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ABSTRACT 
There have been recent proposals advocating the use of additive gene-environment interaction 
instead of the widely used multiplicative scale, as a more relevant public health measure. Using 
gene-environment independence enhances the power for testing multiplicative interaction in 
case-control studies. However, under departure from this assumption, substantial bias in the 
estimates and inflated Type I error in the corresponding tests can occur. This paper extends the 
empirical Bayes (EB) approach previously developed for multiplicative interaction that trades off 
between bias and efficiency in a data-adaptive way, to the additive scale. An EB estimator of 
Relative Excess Risk due to Interaction is derived and the corresponding Wald test is proposed 
with general regression setting under a retrospective likelihood framework. We study the impact 
of gene-environment association on the resultant test with case-control data. Our simulation 
studies suggest that the EB approach uses the gene-environment independence assumption in a 
data-adaptive way and provides power gain compared to the standard logistic regression analysis 
and better control of Type I error when compared to the analysis assuming gene-environment 
independence. We illustrate the methods with data from the Ovarian Cancer Association 
Consortium. 
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INTRODUCTION 
There has been an increasing interest in searching for gene by environment interaction (G x E) in 
the post genome-wide association studies (GWAS) era with limited success (1-5).  A number of 
methods have been proposed for efficient search of G x E effects that use the gene-environment 
independence assumption (2, 6-10). Almost all of these studies have focused on 
testing/estimation of multiplicative interaction, perhaps due to the fact that standard logistic 
regression is the most commonly used tool for analyzing case-control data (11-13). However, it 
has been suggested in the literature that additive interaction is a more relevant public health 
measure (3, 14, 15). If the environmental exposure, say, E, can potentially be modified via an 
intervention, the additive gene x environment interaction measure can quantify the differences 
in the number of cases prevented if the intervention was offered in a prioritized way, across 
strata defined by genetic risk.  This characterization helps with policy questions when limited 
access to an intervention are available. Moreover, the additive measure of interaction 
corresponds more closely to the notion of mechanistic or causal measures of interaction (16, 17).  
Although not commonly recognized, it is possible to test for additive interaction in a logistic 
regression model using case-control data. While a direct estimate of additive interaction on a risk 
difference scale cannot be obtained from case-control data, an alternative parameter, the 
relative excess risk due to interaction (RERI), can be represented in terms of relative risks.  
Assuming that the disease is rare, relative risks can be approximated by corresponding odds 
ratios and thus RERI can be viewed as a function of both main effects and multiplicative 
interaction parameters in a logistic regression model. Standard Delta theorem can be applied to 
provide asymptotic variance and subsequently a Wald test for the null hypotheses RERI=0 can be 
conducted (18-20).  The fact that RERI=0 if and only if the additive null holds provides us a way 
to test for interaction on the additive scale by testing H0: RERI=0. More recently, Han et.al (21) 
developed a likelihood ratio test (LRT) for H0:  RERI=0, applying the retrospective likelihood 
framework proposed by Chatterjee and Carroll (22) that permits the incorporation of the G-E 
independence assumption, and leads to a more powerful test than the previously proposed Wald 
test, in modest sample sizes, for both the unconstrained and constrained ML method. However, 
it is not clear how to extend the LRT in an EB-type adaptive framework and thus we proceeded 
with combining estimates of RERI instead of deriving a combination LRT.  
In this paper, we first consider the binary G, E scenario to illustrate our method for testing 
additive interaction in case-control studies. We provide closed form expressions of the maximum 
likelihood estimates (MLE) and Wald test of the RERI parameter without (unconstrained MLE) 
and with assuming gene-environment independence (constrained MLE). We then extend the 
empirical Bayes-type shrinkage approach for multiplicative G x E interaction proposed by 
Mukherjee et.al (6) to estimate RERI and test for additive interaction. An adaptively weighted 
estimator of RERI that combines the constrained and unconstrained estimators is proposed to 
trade-off between bias and efficiency. Finally, we extend the method to handle a completely 
general regression setting using the retrospective profile likelihood based framework in (22).  We 
conduct a simulation study to compare the performance of various tests and illustrate our 
method by applying it to study the interaction between oral contraceptive pill (OCP) use and 
previously identified genetic factors in a large consortium of case-control studies of ovarian 
cancer. 
 
METHODS 
We first consider a simple setup of an unmatched case-control study with a dichotomous genetic 
factor G and a dichotomous environmental exposure E. Let E=1 (E=0) denote an exposed 
(unexposed) individual and G=1 (G=0) denote whether an individual is a carrier (non-carrier) of 
the susceptible genetic marker. Let D denote the disease status, where D=1 (D=0) stands for an 
affected (unaffected) individual. Let 𝑁0 and 𝑁1 be the number of selected controls and cases, 
respectively. The data can be represented in the form of a 2×4 table as displayed in Web Appendix 
1. 
Let 𝒓𝟎 = (𝑟01, 𝑟02, 𝑟03, 𝑟04)  and 𝒓𝟏 = (𝑟11, 𝑟12, 𝑟13, 𝑟14)  denote the vector of observed cell 
frequencies in the controls and the cases, respectively. Let 𝑟𝐺 = 𝑟03 + 𝑟04 denote the frequency 
of G=1 and 𝑟𝐸 = 𝑟02 + 𝑟04  denote the frequency of E=1 among controls. Let 𝒑𝟎 =
(𝑝01, 𝑝02, 𝑝03, 𝑝04) and 𝒑𝟏 = (𝑝11, 𝑝12, 𝑝13, 𝑝14) denote the true population parameters of the 
cell probabilities corresponding to a particular G-E configuration in the underlying control and 
case populations respectively. Let 𝑝𝐺 = 𝑝03 + 𝑝04 denote the marginal prevalence of G=1 among 
controls and 𝑝𝐸 = 𝑝02 + 𝑝04  denote the marginal prevalence of E=1 among controls. The 
observed vectors of the cell counts can be viewed as random draws from two independent 
multinomial distributions in controls and cases respectively, namely, 𝒓𝟎~Multinomial (𝑁0, 𝒑𝟎) 
and 𝒓𝟏~Multinomial(𝑁1, 𝒑𝟏).  
Let us introduce the following notation for the key parameters of interest. Let 𝑂𝑅𝐸 =
𝑃(𝐷=1|𝐸=1,𝐺=0)
𝑃(𝐷=0|𝐸=1,𝐺=0)
𝑃(𝐷=1|𝐸=0,𝐺=0)
𝑃(𝐷=0|𝐸=0,𝐺=0)
⁄ = 𝑝01𝑝12/𝑝02𝑝11 denote the odds ratio associated with E for non-
susceptible individuals (G=0), 𝑂𝑅𝐺 =
𝑃(𝐷=1|𝐺=1,𝐸=0)
𝑃(𝐷=0|𝐺=1,𝐸=0)
𝑃(𝐷=1|𝐺=0,𝐸=0)
𝑃(𝐷=0|𝐺=0,𝐸=0)
⁄ = 𝑝01𝑝13/𝑝03𝑝11  denote 
the odds ratio associated with G for unexposed individuals (E=0) and 𝑂𝑅𝐺𝐸 =
𝑃(𝐷=1|𝐸=1,𝐺=1)
𝑃(𝐷=0|𝐸=1,𝐺=1)
𝑃(𝐷=1|𝐸=0,𝐺=0)
𝑃(𝐷=0|𝐸=0,𝐺=0)
⁄ = 𝑝01𝑝14/𝑝04𝑝11 denote the joint odds ratio associated with the 
sub-group G=1 and E=1 compared to the reference group of G=0 and E=0. The multiplicative 
interaction parameter 𝜓 is defined as: 
𝜓 =
𝑂𝑅𝐺𝐸
𝑂𝑅𝐺𝑂𝑅𝐸
=
𝑝02𝑝03𝑝11𝑝14
𝑝01𝑝04𝑝12𝑝13
=
𝑝11𝑝14
𝑝12𝑝13
exp(𝜃𝐺𝐸)
, where 𝜃𝐺𝐸 = log
𝑝01𝑝04 
𝑝02𝑝03
. 
The parameter  𝜃𝐺𝐸  represents the log odds ratio between G and E among the controls, 
characterizing the gene-environment association. In the additive scale, the measure of 
interaction is defined as: 
padditive =  [P(D = 1|E = 1, G = 1) − P(D = 1|E = 0, G = 0)]
− [P(D = 1|E = 1, G = 0) − P(D = 1|E = 0, G = 0)]
− [P(D = 1|E = 0, G = 1) − P(D = 1|E = 0, G = 0)] 
= P(D = 1|E = 1, G = 1) − P(D = 1|E = 1, G = 0) − P(D = 1|E = 0, G = 1) +
P(D = 1|E = 0, G = 0)     (1)      
Dividing (1) throughout by P(D = 1|E = 0, G = 0) we obtain a new measure relative excess risk 
due to interaction (RERI) 
                                                𝑅𝐸𝑅𝐼𝑅𝑅 = 𝑅𝑅𝐺𝐸 − 𝑅𝑅𝐺 − 𝑅𝑅𝐸 + 1.         (2) 
When the disease is rare, OR approximates RR. Hence, we have  
𝑅𝐸𝑅𝐼𝑂𝑅 ≈ 𝑂𝑅𝐺𝐸 − 𝑂𝑅𝐺 − 𝑂𝑅𝐸 + 1.          (3) 
Note that by (1) and (3), testing  H0: padditive = 0 is equivalent to testing H0: 𝑅𝐸𝑅𝐼𝑅𝑅 = 0, which 
is typically translated into H0: 𝑅𝐸𝑅𝐼𝑂𝑅 = 0   in a case-control study as described in VanderWeele 
(23). After defining the above relevant parameters of interest, we use the definition of RERI in 
equation (3) in terms of ORs to proceed with inference under case-control sampling assuming 
the disease is rare for all configurations of G and E. 
Unconstrained maximum likelihood estimation 
The unconstrained maximum-likelihood (UML) estimate for all OR parameters mentioned above 
are obtained by simply substituting 𝑝𝑑𝑗 with its MLE, ?̂?𝑑𝑗 =   𝑟𝑑𝑗/𝑁𝑑, implying, 
               ?̂?𝑢𝑚𝑙 =
𝑂?̂?𝐺𝐸
𝑂?̂?𝐺𝑂?̂?𝐸
=
𝑟02𝑟03𝑟11𝑟14
𝑟01𝑟04𝑟12𝑟13
,           ?̂?𝑢𝑚𝑙
2 = 𝑉𝑎𝑟(log(?̂?𝑢𝑚𝑙)) = ∑ ∑
1
𝑟𝑑𝑗
4
𝑗=1
1
𝑑=0  
The G-E association log odds ratio in controls can also be estimated as 𝜃𝐺𝐸 = log
𝑟01𝑟04
𝑟02𝑟03
.  
The UML estimate of RERI can be easily obtained by plugging the corresponding estimated ORs 
in an unconstrained model into equation (3) and by the invariance property of MLE, serves as a 
consistent and asymptotically unbiased estimate of RERI regardless of the gene-environment 
independence assumption.  
𝑅𝐸𝑅?̂?𝑢𝑚𝑙 =
𝑟01𝑟14
𝑟11𝑟04
−
𝑟01𝑟13
𝑟11𝑟03
−
𝑟01𝑟12
𝑟11𝑟02
+ 1    (4) 
Note that 𝒓𝟎 and 𝒓𝟏 are realizations from two independent multinomial distributions, and we 
can employ Delta method (Web Appendix 2) to obtain the asymptotic variance of 𝑅𝐸𝑅?̂?uml, which 
is the same as noted in (17-19). The Wald test for interaction is based on the standardized Z 
statistic  𝑍𝑢𝑚𝑙 = 𝑅𝐸𝑅?̂?𝑢𝑚𝑙/√𝑉𝑎?̂?(𝑅𝐸𝑅?̂?𝑢𝑚𝑙)  which follows a N (0,1) distribution under the null 
RERI=0. 
Constrained maximum likelihood estimation 
Under G-E independence among controls, i.e. 𝜃𝐺𝐸 = 0 and rare disease assumptions, Zhang et.al 
(24) proposed the constrained MLEs (CML) for 𝒑𝟎 and 𝒑𝟏 as follows: ?̂?01 =
(𝑟01+𝑟03)(𝑟01+𝑟02)
𝑁0
2 ,  
?̂?02 =
(𝑟01+𝑟02)(𝑟02+𝑟04)
𝑁0
2 , ?̂?03 =
(𝑟01+𝑟03)(𝑟03+𝑟04)
𝑁0
2 , ?̂?04 =
(𝑟02+𝑟04)(𝑟03+𝑟04)
𝑁0
2  and ?̂?1𝑗 =
𝑟1𝑗
𝑁1
, 𝑗 = 1,2,3,4. 
We obtain the corresponding OR estimates by substituting 𝑝𝑑𝑗 with its constrained MLE under 
G-E independence, 𝑂?̂?𝐸 =
𝑟12(𝑟01+𝑟03)
𝑟11(𝑟02+𝑟04)
 , 𝑂?̂?𝐺 =
𝑟13(𝑟01+𝑟02)
𝑟11(𝑟03+𝑟04)
 , 𝑂?̂?𝐺𝐸 =
𝑟14(𝑟01+𝑟02)(𝑟01+𝑟03)
𝑟11(𝑟02+𝑟04)(𝑟03+𝑟04)
 and 
?̂?cml =
𝑟11𝑟14
𝑟12𝑟13
, ?̂?𝑐𝑚𝑙
2 = 𝑉𝑎𝑟(log(?̂?𝑐𝑚𝑙)) = ∑
1
𝑟1𝑗
4
𝑗=1 . Note that the estimated multiplicative 
interaction parameter ?̂?  is a function of only 𝒓𝟏, and is identical to the case-only estimator. 
The CML estimate of RERI can be computed by plugging the estimated ORs under the constraint 
into equation (3). Formally, the CML estimator for RERI is given by 
𝑅𝐸𝑅?̂?𝑐𝑚𝑙 =
(𝑟01+𝑟03)(𝑟01+𝑟02)𝑟14
(𝑟02+𝑟04)(𝑟03+𝑟04)𝑟11
−
(𝑟01+𝑟02)𝑟13
(𝑟03+𝑟04)𝑟11
−
(𝑟01+𝑟03)𝑟12
(𝑟02+𝑟04)𝑟11
+ 1.   (5) 
Under G-E independence assumption among controls, the CML estimator is consistent and 
asymptotically unbiased for the true RERI parameter. It is more precise than the UML estimator 
of RERI in equation (4) based on our simulations. The asymptotic variance of the CML estimator 
can also be approximated by Delta method, which is shown in Web Appendix 3. The Wald test 
for RERI in a constrained model again uses the standardized Z statistic  𝑍𝑐𝑚𝑙 = 𝑅𝐸𝑅?̂?𝑐𝑚𝑙/
√𝑉𝑎?̂?(𝑅𝐸𝑅?̂?𝑐𝑚𝑙) , and the power of the test is slightly lower than LRT for additive interaction in 
(21) as will be illustrated through our simulations. Under violation of gene-environment 
independence assumption, 𝜃𝐺𝐸 ≠ 0, the CML estimate is asymptotically biased for the true RERI 
parameter and the tests are invalid. 
 
Empirical Bayes estimation 
Mukherjee et.al (6) proposed an empirical Bayes (EB) estimator of the multiplicative interaction 
which shrinks the UML and CML estimators in a data-adaptive way. It relaxes G-E independence 
assumption and makes a trade-off between bias and efficiency. Formally, the EB estimator of 
multiplicative interaction is given by  
log (?̂?𝐸𝐵) =
?̂?𝑢𝑚𝑙
2
?̂?𝐺𝐸
2 +?̂?𝑢𝑚𝑙
2 log (?̂?𝑐𝑚𝑙) +
?̂?𝐺𝐸
2
?̂?𝐺𝐸
2 +?̂?𝑢𝑚𝑙
2 log (?̂?𝑢𝑚𝑙) ,   (6) 
where ?̂?𝑐𝑚𝑙 =  
𝑟11𝑟14
𝑟12𝑟13
 ,  ?̂?𝑢𝑚𝑙 =  
𝑟02𝑟03𝑟11𝑟14
𝑟01𝑟04𝑟12𝑟13
  , ?̂?𝑢𝑚𝑙
2 = ∑ ∑
1
𝑟𝑑𝑗
4
𝑗=1
1
𝑑=0  and 𝜃𝐺𝐸 = log
𝑟01𝑟04
𝑟02𝑟03
.  
We employ the same idea of adaptive weighting and propose the EB estimator for RERI as, 
𝑅𝐸𝑅?̂?𝐸𝐵 =
(𝑅𝐸𝑅?̂?𝑢𝑚𝑙−𝑅𝐸𝑅?̂?𝑐𝑚𝑙)
2
𝑉𝑎?̂?(𝑅𝐸𝑅?̂?𝑢𝑚𝑙)+(𝑅𝐸𝑅?̂?𝑢𝑚𝑙−𝑅𝐸𝑅?̂?𝑐𝑚𝑙)2
𝑅𝐸𝑅?̂?𝑢𝑚𝑙 +
𝑉𝑎?̂?(𝑅𝐸𝑅?̂?𝑢𝑚𝑙)
𝑉𝑎?̂?(𝑅𝐸𝑅?̂?𝑢𝑚𝑙)+(𝑅𝐸𝑅?̂?𝑢𝑚𝑙−𝑅𝐸𝑅?̂?𝑐𝑚𝑙)2
𝑅𝐸𝑅?̂?𝑐𝑚𝑙      
= 𝑅𝐸𝑅?̂?𝑢𝑚𝑙 + 𝐾(𝑅𝐸𝑅?̂?𝑐𝑚𝑙 − 𝑅𝐸𝑅?̂?𝑢𝑚𝑙)       (7),  
where 𝐾 = 𝑉(𝑉 + ?̂??̂?𝑇)−1 is a shrinkage factor of the same form as defined in Chen et.al (25) 
with ?̂? = 𝑅𝐸𝑅?̂?𝑢𝑚𝑙 − 𝑅𝐸𝑅?̂?𝑐𝑚𝑙 and 𝑉 = 𝑉𝑎?̂?(𝑅𝐸𝑅?̂?𝑢𝑚𝑙). To explain the intuitive rationale behind 
the estimator, observe that as 𝜃𝐺?̂? → 0, i.e. as the data provide the evidence in favor of G-E 
independence,  𝑅𝐸𝑅?̂?𝑢𝑚𝑙 − 𝑅𝐸𝑅?̂?𝑐𝑚𝑙 → 0 , the estimator puts more weight on CML estimator to 
gain more efficiency, and as 𝜃𝐺?̂? → ∞. i.e. as the G-E dependence becomes stronger in control 
population, 𝑅𝐸𝑅?̂?𝑢𝑚𝑙 − 𝑅𝐸𝑅?̂?𝑐𝑚𝑙  becomes larger, then the EB estimator puts more weight on 
UML estimator to reduce bias.  In large samples, the EB estimator converges to the UML estimate 
and thus is asymptotically unbiased for the true RERI parameter (6). The asymptotic variance of 
𝑅𝐸𝑅?̂?𝐸𝐵  is derived by Delta method (See Web Appendix 4), assuming 𝑉𝑎?̂?(𝑅𝐸𝑅?̂?𝑢𝑚𝑙)  as a 
constant relative to the order of magnitude of the point estimates (6). We use Wald test for the 
EB estimator based on the standardized Z statistic  𝑍𝐸𝐵 = 𝑅𝐸𝑅?̂?𝐸𝐵/√𝑉𝑎?̂?(𝑅𝐸𝑅?̂?𝐸𝐵) .  
Remark 1. We also considered two other forms of adaptive weights. One is to modify the 
shrinkage factor K in (7) and let 𝑘∗̂ = 𝜃𝐺𝐸  instead of  𝑅𝐸𝑅?̂?𝑢𝑚𝑙 − 𝑅𝐸𝑅?̂?𝑐𝑚𝑙 , namely,  𝑅𝐸𝑅𝐼̂ 𝐸𝐵1 =
𝑅𝐸𝑅?̂?𝑢𝑚𝑙 + 𝐾
∗(𝑅𝐸𝑅?̂?𝑐𝑚𝑙 − 𝑅𝐸𝑅?̂?𝑢𝑚𝑙), where 𝐾
∗ = 𝑉 (𝑉 + 𝜅∗̂𝜅∗̂
𝑇
)
−1
. The other is to plug in the 
EB estimates,  𝑂?̂?𝐸𝐵 , obtained from using the retrospective likelihood framework in (6) as 
implemented in R package CGEN (6, 22, 25) directly into equation (3), namely, 𝑅𝐸𝑅?̂?𝐸𝐵2 =
𝑂?̂?𝐺𝐸 − 𝑂?̂?𝐺 − 𝑂?̂?𝐸 + 1 , where all estimated ORs are EB estimates proposed under the 
multiplicative model. The EB estimator we proposed in equation (7) demonstrates superior 
performance among the three choices, based on our simulation study.  
Remark 2:  As shown in Chen et.al (25), the asymptotic theory for CML and consequently EB is 
non-regular under the independence assumption. The Delta method does not technically apply 
for estimating the asymptotic variance. Theoretically, the test statistic also fails to be 
asymptotically normal under G-E independence (25, 26).  However, in practice, the estimated 
variance derived by the Delta Method approximates the empirical variance very well as noted in 
the simulation studies (see Web Appendix 5, Web Tables 1-2 and Web Figures 1-2). Under G-E 
dependence, EB estimate converges in large sample to UML estimate and thus to the true RERI 
parameter and standard likelihood asymptotics holds (6). 
Profile likelihood framework for general regression setting 
Consider the retrospective likelihood considered in Chatterjee and Carroll (22), Mukherjee et.al 
(6) and as implemented in the R package CGEN: 
𝑃(𝐺, 𝐸, 𝒁|𝐷) =
𝑃(𝐷 = 1|𝐺, 𝐸, 𝒁)𝑃(𝐺|𝐸, 𝒁)𝑃(𝐸, 𝒁)
∑ 𝑃(𝐷 = 1|𝐺, 𝐸, 𝒁)𝑃(𝐺|𝐸, 𝒁)𝑃(𝐸, 𝒁)𝐺,𝐸,𝒁
                   (8) 
The three ingredients of the above retrospective likelihood are: 
(a) The logistic regression disease risk model of interest with multiplicative GEI parameter: 
 logit P(𝐷 = 1|𝐺, 𝐸, 𝒁) = 𝛽0 + 𝛽𝐺𝐺 + 𝛽𝐸𝐸 + 𝛽𝐺𝐸𝐺×𝐸 + 𝜷𝒁
𝑻𝒁 , where 𝒁  denotes other 
covariates.  
(b) logit P(𝐺|𝐸, 𝒁) = 𝜃0 + 𝜃𝐺𝐸𝐸 + 𝜽𝑮𝒁
𝑻 𝒁.  While this is the gene model used for UML, allowing 
G-E dependence, in the CML method, P(𝐺|𝐸, 𝒁) reduces to P(𝐺|𝒁) under the assumption of G-
E independence conditional on 𝒁, implying 𝜃𝐺𝐸 ≡ 0  .  
(c) The distribution P(𝐸, 𝒁) is allowed to be completely non-parametric. We then maximize the 
retrospective likelihood using existing routines in CGEN to obtain  ?̂?𝑢𝑚𝑙 and  ?̂?𝑐𝑚𝑙 , the vector of 
all the parameter estimates of the disease risk model in (a), namely, (𝛽0, 𝛽𝐺 , 𝛽𝐸 , 𝛽𝐺𝐸 , 𝜷𝒁). 
When it comes to defining RERI with a general G and E variable adjusting for covariates Z,  
particularly with case-control data, as described in VanderWeele (23), let us denote by 
𝑅𝐸𝑅𝐼𝑂𝑅(𝐸0, 𝐸1, 𝐺0, 𝐺1) the relative excess risk due to interaction by replacing risk ratios with 
corresponding  odds ratios in the RERI expression in (3) as typically done in a case-control study. 
With general continuous and ordinal exposures one has to consider the magnitude of change in 
exposure for which one is examining the interaction. Let us consider the situation when 
environmental risk factor changes from 𝐸0 to 𝐸1 and genetic risk factor changes from 𝐺0 to 𝐺1 
but other covariates 𝒛 are held constant. Formally, it is defined as 
𝑅𝐸𝑅𝐼𝑂𝑅(𝐸0, 𝐸1, 𝐺0, 𝐺1) 
= 𝑂𝑅(𝐺1, 𝐸1) − 𝑂𝑅(𝐺1, 𝐸0) − 𝑂𝑅(𝐺0, 𝐸1) + 1 
= exp{𝛽𝐺(𝐺1 − 𝐺0) + 𝛽𝐸(𝐸1 − 𝐸0) + 𝛽𝐺𝐸(𝐺1×𝐸1 − 𝐺0×𝐸0)}
− exp{𝛽𝐸(𝐸1 − 𝐸0) + 𝛽𝐺𝐸𝐺0×(𝐸1 − 𝐸0)}
− exp{𝛽𝐺(𝐺1 − 𝐺0) + 𝛽𝐺𝐸(𝐺1 − 𝐺0)×𝐸0} + 1 
= 𝑓(𝛽𝐺 , 𝛽𝐸 , 𝛽𝐺𝐸 ) ≈ 𝑅𝐸𝑅𝐼(𝐸0, 𝐸1, 𝐺0, 𝐺1)    (9) 
This last approximation of risk ratios by odds ratios holds when the outcome is rare in each 
stratum defined by the two exposures or when controls are selected from the entire population, 
not just the non-cases (27). More generally, if G and E are both categorical factors with I and J 
levels with coefficients corresponding to different levels of each factor, then 𝛽𝐺 , 𝛽𝐸 , 𝛽𝐺𝐸  in 
equation (9) become (I-1), (J-1) and (I-1)(J-1) dimensional vectors instead of scalars. Note that 
𝑅𝐸𝑅?̂?𝑢𝑚𝑙 = 𝑓( ?̂?𝑢𝑚𝑙)  and 𝑅𝐸𝑅?̂?𝑐𝑚𝑙 = 𝑓( ?̂?𝑐𝑚𝑙) , can be viewed as function of UML and CML 
estimates of relative risk parameters, where f is the function in equation (9). The variance of 
𝑅𝐸𝑅?̂?𝑢𝑚𝑙  and 𝑅𝐸𝑅?̂?𝑐𝑚𝑙 can be calculated by Delta method. The EB estimator of RERI is same as in 
equation (7) and its estimated variance is calculated by Delta method using the joint distribution 
of (?̂?𝒖𝒎𝒍, ?̂?𝒄𝒎𝒍) as proposed by Mukherjee et.al (6) (Web Appendix 6). The Wald tests for the 
three estimators are all based on the standardized Z statistic. We have provided general codes 
to test for RERI at (28).  
 
Example: Analysis of G x E interactions in case-control studies of ovarian cancer 
Epithelial ovarian cancer is one of the most common malignancies of the female reproductive 
tract. Approximately 14,240 women died from ovarian cancer in 2016 in the United States, 
causing more deaths than any other cancer of the female reproductive system. There are several 
well-established non-genetic risk factors for ovarian cancer (29-35), and recent genome-wide 
association studies have identified and replicated 18 variants that influence disease risk (36). To 
this end, the Ovarian Cancer Association Consortium (OCAC) has undertaken an effort to study 
interactions focusing on the 18 confirmed single nucleotide polymorphisms (SNPs) and seven 
well-established risk factors: race, history of endometriosis, first degree family history of ovarian 
cancer, oral contraceptive pill (OCP) use, parity, tubal ligation, and age. In our illustrative analysis, 
we focus on OCP x SNP interaction and use genetic data from 15 OCAC studies that also have 
data on epidemiologic risk factors. 
Each SNP is coded as the number of risk alleles a subject carried and all subsequent analysis 
assumed this additive genetic susceptibility model. Published ORs of the 18 confirmed loci in Web 
Table 3 are from analyses presented in Collaborative Oncological Gene-Environment Study (37-
44). As a parsimonious and succinct way of summarizing the effects of genetic variants across all 
loci for each subject, we construct a "genetic risk score" (GRS) variable as the sum of the risk 
allele counts across all loci and a “weighted genetic risk score” (WGRS) as the weighted sum, 
where the weight for each individual SNP is determined by the published log OR in large meta-
analysis. Polygenic risk scores have been used for risk stratification in multiple G x E papers 
recently (3,45). Analysis of marginal effect for GRS and WGRS is shown in Web Table 4. Each 
environmental factor is coded as a categorical variable as described in Web Table 5. The merged 
G × E dataset has a sample size of 11,661 subjects with European ancestry, with 4,135 cases and 
7,526 controls from 13 study sites (Web Table 6). 
To illustrate our inference for interactions between OCP use (1 =ever and 0 =never) and genetic 
risk factors we consider both single SNP x OCP and (W)GRS x OCP interaction. For single SNP 
analysis, we consider the top two hits in the 18 confirmed loci, i.e. rs62274042 (SNP1) and 
rs10962691 (SNP2) as reported in Web Table 3. We used additive coding for our SNP x OCP 
analysis. For GRS and WGRS, we use the quartiles in controls to define a categorical variable with 
four categories. The analysis model adjusts for study site and all other environmental risk factors 
except race. 
 
Simulation design 
In our simulation study, we first investigate the Type I error, standard power at level 𝛼 and power 
at empirical 𝛼 (empirical Type I error is used to report power in situations where Type I error is 
not maintained) of Wald tests for 𝑅𝐸𝑅?̂?𝑢𝑚𝑙 , 𝑅𝐸𝑅?̂?𝑐𝑚𝑙  and 𝑅𝐸𝑅?̂?𝐸𝐵  under various alternative 
values of RERI across a spectrum of scenarios, varying the strength of G-E association, main 
effects of G and E, minor allele frequency of G, prevalence of exposure E, test size and sample 
sizes. We compare the power of Wald test for 𝑅𝐸𝑅?̂?𝑐𝑚𝑙 with the previously proposed LRT for 
additive interaction under G-E independence (21). We also explore estimation properties like the 
absolute relative bias and MSE of the three estimators as well as those of two alternative 
proposals, 𝑅𝐸𝑅?̂?𝐸𝐵1 and 𝑅𝐸𝑅?̂?𝐸𝐵2. Note that both RERI and multiplicative interaction parameters 
are obtained from the underlying true logistic regression model  
                                logit P(D = 1|𝐺, 𝐸) = 𝛽0 + 𝛽𝐸𝐸 + 𝛽𝐺𝐺 + 𝛽𝐺𝐸𝐺𝐸,  
where RERI=exp(𝛽𝐺 + 𝛽𝐸 + 𝛽𝐺𝐸) − exp(𝛽𝐺) − exp(𝛽𝐸) + 1,  and 𝜓 = exp(𝛽𝐺𝐸 ), so that the 
value of RERI is well-defined given 𝜓 and vice versa, once the main effect parameters 𝑂𝑅𝐺 =
exp(𝛽𝐺) and 𝑂𝑅𝐸 = exp(𝛽𝐸)  are specified.  
We set prevalence of G and E in controls, 𝑝𝐺 = (0.1, 0.2, 0.3) and 𝑝𝐸 = (0.3, 0.4, 0.5); the main 
effects 𝑂𝑅𝐺 = (1.1, 1.2, 1.3) ;  𝑂𝑅𝐸 = (1.3, 1.5, 1.7) ; sample size 𝑁0 = 𝑁1 = (4000, 20000) ; 
size of test α = (0.05, 5×10−6); the strength of G-E association, exp(𝜃𝐺𝐸), change from 0.8 to 
1.2 at a grid of 0.1 and RERI change from 0 to 1.5 with a grid of 0.1. The number of simulated 
datasets is 1000 when α = 0.05 and is 106 when α = 5×10−6. The population parameters of cell 
probability 𝒑𝟎 and 𝒑𝟏 are defined by solving the equations in Web Appendix 7 (9, 46): 
We generate data independently from the two multinomial distributions corresponding to the 
case and control populations, according to the above probabilities with number of cases and 
control as 𝑁0,  𝑁1, respectively. We also considered another simulation setting to mimic a large-
scale genomewide search of interactions where we use random distribution for the parameters 
corresponding to the set of null markers. We first compute the UML, CML and EB estimators 
using equations (4), (5), and (7) and then compare their Type I error, power, power at empirical 
𝛼 , absolute relative bias and MSE. Type I error over 1000 replications. Power are estimated by 
the proportion of null hypothesis H𝟎: 𝑅𝐸𝑅𝐼 = 0 rejected at the given level of significance 𝛼, i.e. 
the proportion of times |𝑍|>𝑍1−𝛼/2 , where Z is Wald test statistic.  Power at empirical 𝛼 is a 
modified power which utilizes an empirical P value threshold as the rejection rule to control the 
Type I error around the given significance level when the Type I error at the desired nominal level 
is not maintained. The absolute relative bias is calculated by averaging |𝑅𝐸𝑅?̂? − 𝑅𝐸𝑅𝐼|/𝑅𝐸𝑅𝐼 
and MSE is calculated by averaging (𝑅𝐸𝑅?̂? − 𝑅𝐸𝑅𝐼)
2
.  
RESULTS 
Ovarian cancer data example 
The distributions of GRS and WGRS in cases and controls are displayed in Web Figure 3. Relative 
to the control distributions, the upper tails of the case distributions are shifted slightly rightward. 
We calculate UML, CML and EB estimators of interactions in both multiplicative and additive 
scale. The estimates, corresponding CIs and P-values of Wald test are shown in Table 1. In 
SNP1×OCP analysis, the strength of G-E association is modest: exp (θGE) =1.07 (95% CI 
[0.94,1.21]), EB estimate of RERI is -0.16 with 95% CI [-0.50,0.18], where the weight on 𝑅𝐸𝑅?̂?𝑢𝑚𝑙  
is 43%. In SNP2×OCP analysis, the G-E association seems weaker with exp(θGE)=0.96 (95% CI 
[0.83,1.11]). EB estimate of RERI is 0.04 with 95% CI [-0.11,0.18], with its weight on 𝑅𝐸𝑅?̂?𝑢𝑚𝑙  
decreasing to 11%. The confidence intervals corresponding to 𝑅𝐸𝑅?̂?𝐸𝐵 are narrower compared 
to the corresponding intervals for  𝑅𝐸𝑅?̂?𝑢𝑚𝑙. The point estimate 𝑅𝐸𝑅?̂?𝐸𝐵 lies between 𝑅𝐸𝑅?̂?𝑢𝑚𝑙  
and 𝑅𝐸𝑅?̂?𝑐𝑚𝑙 , reflecting the combined efficiency-robustness feature of the EB estimator. In 
WGRS×OCP analysis we report interactions associated with a change of OCP from 0 to 1 (ever 
users to never users) and WGRS from the lowest to the highest quartile (as defined through 
distribution of WGRS in controls) the multiplicative measure of interaction ?̂?𝐸𝐵 is not significant 
at α=0.05 but 𝑅𝐸𝑅?̂?𝐸𝐵 departs from 0 significantly with EB estimate of RERI -0.52(95% CI [-0.91, -
0.13]) and has a very small P-value, 0.009. 
To visually present the results, we fit a standard logistic regression model including the main 
effects of OCP use and quartiles of WGRS as a categorical factor, and an interaction term for 
WGRS×OCP adjusting for study sites and other risk factors. Figure 1 shows the odds ratio of OCP 
and corresponding CI stratified by WGRS. The odds ratio of OCP is 0.61 (0.50,0.74) in the lowest 
WGRS quartile and 0.51 (0.43,0.60) in the highest quartile. The overlapping CIs indicate a non-
significant multiplicative interaction. Additionally, if we assume that approximately 1.3 percent 
of women will be diagnosed with ovarian cancer at some point during their lifetime (47) and 70% 
women will use OCP at some point in their life in this population (estimated from the OCAC data), 
we present the estimated lifetime risk of ovarian cancer and corresponding 95% CI within each 
WGRS stratum in Figure 2, for OCP users and non-users. Estimates of lifetime absolute risk for 
OCP users is 0.75% (0.57%, 0.98%) and 1.23% (1.00%, 1.51%) for OCP non-users in the lowest 
WGRS stratum with a difference of 0.48% (0.02%, 0.94%) and the corresponding numbers were 
1.40% (1.08%, 1.81%) and 2.72% (2.05%, 3.60%) with a difference of 1.32% (0.24%, 2.52%) for 
subjects in the highest WGRS stratum, showing why the test for RERI is significant.   
Results from the Simulation Study 
Type I error. Web Table 7 presents Type I errors for different tests of RERI. One can observe that 
UML maintains nominal level α across different choices of  θGE . An inflated Type I error 
associated with CML is observed when G-E independence assumption is violated. EB test is valid 
when exp(θGE)=1 and has a modest inflation on Type I error when G is associated with E. The 
maximal observed Type I error of EB at α=0.05 is 0.099 when sample size is 40,000, test size is 
0.05 and exp (θGE)=1.1. Web Figure 4 presents how Type I error varies with exp(θGE) for the 
three estimators. The Type I error of CML is very sensitive to the G-E association but the 
performance of EB is relatively robust with marked reduction in Type I error compared to CML. 
The findings remain similar for different choices of  𝑝𝐺, 𝑝𝐸, 𝑂𝑅𝐺 and 𝑂𝑅𝐸 (Web Tables 8-9). 
Results from additional simulation mimicking a Genomewide Association Study: To justify the use 
of EB estimator in genomewide assessment of G-E interaction, we conduct another simulation 
study similar to that in Reference (8), which generates 2000 cases and controls with 1 causal 
marker together with M-1 null markers where M is 10,000. G-E independence parameter 𝜃𝐺𝐸  in 
controls have a random mixture distribution with point mass around independence and pind is 
the proportion of null loci that follow G-E independence. The detailed simulation setting is 
presented in Web Appendix 8. The expected nominal level for both familywise error rate and 
expected number of false positives is 0.05 when G-E independence holds. However, if there is G-
E dependence for a proportion of markers, Bonferroni correction cannot guarantee the nominal 
level for EB and CML.  As shown in Table 2, when 99% of the markers are independent, EB 
maintains familywise Type I error rate of 0.06 and expected number of false positives of 0.06.  
The performance of CML is significantly worse with familywise error rate of 99% and expected 
number of false positives 3.76. 
Power. Figure 3 shows the power curves of Wald test for three estimators with H0: 𝑅𝐸𝑅𝐼 =
0 under different strengths of G-E association (Web Tables 10-15). It is hard to compare the 
estimated powers directly from the figure as the inflated Type I error of CML and EB leads to the 
misleading high power values. Hence, we assess the power at empirical α for CML and EB, which 
controls the corresponding Type I error at 0.05. UML is the most efficient when exp(θGE)=0.8, 
CML is the most efficient when exp(θGE)=1 and 1.2, and EB power always lies in between. For a 
sample numerical comparison, let us compare the powers of the three approaches at RERI=0.5 
to represent one typical scenario. When exp(θGE)=0.8, the empirical power of EB (0.275) is 41% 
lower than UML (0.672), meanwhile CML has nearly 0 power. When exp(θGE)=1, the empirical 
power of EB (0.870) is 25% higher than UML (0.693) but 10% lower than CML (0.970). When 
exp(θGE)=1.2, the empirical power of EB (0.718) is slightly higher than UML (0.714) but 28% 
lower than CML (0.993). We then compare the power of Wald test for 𝑅𝐸𝑅?̂?𝑐𝑚𝑙  with LRT for 
additive interaction shown in Web Figure 5. The power of LRT is uniformly slightly higher than 
the Wald test with true value of RERI varying from 0 to 0.5 with a grid of 0.1. Absolute relative 
bias and MSE results are relegated to Web Appendix 9, Web Tables 16-19, Web Figure 6. 
 
 
 
DISCUSSION 
In this paper, we extend the EB estimator of gene-environment interaction proposed earlier on 
the multiplicative scale to additive scale in case-control studies. The EB estimator exploits G-E 
independence assumption to perform a trade-off between bias and efficiency. The simulation 
study showed that the test based on the EB estimator can provide a good control of Type I error 
and it is always intermediate between UML and CML with respect to power, relative bias and 
mean squared error. In the ovarian cancer data example, we conducted a (W)GRSOCP analysis 
to illustrate the application of the proposed method. We found a significant additive 
(W)GRS×OCP interaction but insignificant multiplicative interaction at =0.05. 
As an inherent limitation of case-control studies, only the relative risk can be estimated, e.g. RERI, 
instead of the underlying direct measure, e.g. padditive in equation (1), because 𝑝11 can only be 
estimated from cohort data. However, general population incidence data from cohort studies 
can be combined with case-control risk-factor models to estimate absolute risks in population-
based case-control studies (48), as we carried out in Figure 2. If the rare disease assumption for 
each configuration of G and E does not hold, approximating RR by OR in case-control studies will 
not be accurate and thus the proposed estimate of RERI may depart from the truth. By using the 
retrospective maximum likelihood estimates, using prior guesses for disease prevalence and 
adaptive combinations like EB procedure we can make our inference less biased under violation 
of the rare disease and gene-environment independence assumptions. 
There is increasingly more interest in inference for additive interaction using case-control data. 
Tchetgen –Tchetgen et.al (49) described a general approach to test for G x E additive interaction 
exploiting G-E independence which is robust to possible misspecification of main effects in the 
outcome regression. Han et.al (50) proposed a score test for UML and CML estimators of genetic 
associations under the additive null. In the future, it is of analytical interest to establish an EB 
version of adaptive score test and adaptive LRT as most of the recent work has been in terms of 
combining estimators but not tests.  
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Table 1.  Estimates and 95% confidence interval corresponding to SNP/GRS x Oral Contraceptive 
Pill Use Interaction under Both Multiplicative and Additive Scale with accompanying P-values 
from Wald Tests 
 
Interaction Multiplicative (𝝍) Additive (RERI) 
SNP1a×OCPb Estimatec  95% CI P-value Estimated 95% CI P-value 
UML 0.94 0.73, 1.22 0.645 -0.25 -0.60, 0.10 0.162 
CML 1.06 0.88, 1.28 0.548 -0.09 -0.33, 0.14 0.432 
EB 1.00 0.78, 1.29 0.970 -0.16 -0.50, 0.18 0.348 
SNP2a×OCP         
UML 0.93 0.82, 1.05 0.255 0.08 -0.18, 0.34 0.552 
CML 0.94 0.85, 1.04 0.224 0.03 -0.18, 0.25 0.757 
EB 0.94 0.85, 1.04 0.222 0.04 -0.11, 0.18 0.598 
GRSd×OCP         
UML 0.82 0.65, 1.02 0.073 -0.64 -1.01, -0.27 0.001 
CML 0.92 0.77, 1.08 0.305 -0.43 -0.68, -0.18 0.001 
EB 0.86 0.69, 1.07 0.197 -0.54 -0.93, -0.16 0.005 
WGRSd×OCP         
UML 0.90 0.76, 1.06 0.212 -0.61 -0.99, -0.23 0.002 
CML 0.95 0.83, 1.08 0.417 -0.40 -0.67, -0.14 0.003 
EB 0.93 0.81, 1.08 0.366 -0.52 -0.91, -0.13 0.009 
 
Abbreviations: CML, constrained maximum-likelihood; EB, empirical Bayes; GRS, genetic risk 
score; RERI, relative excess risk due to interaction; UML, unconstrained maximum-likelihood; 
WGRS, weighted genetic risk score. 
a SNP1 denotes rs62274042 and SNP2 denotes rs10962691. Marginal disease odds ratios 
corresponding to these SNPs are 1.45 (1.37, 1.54) and 1.25 (1.20, 1.30) respectively. 
b OCP=1 if the individual ever used OCP and OCP=0 if never. 
c The analysis is based on subjects with European ancestry, using data on 4,135 cases and 7,526 
controls from 13 study sites from the Ovarian Cancer Association Consortium. The model adjusts 
for history of endometriosis, first degree family history of ovarian cancer, parity, tubal ligation, 
age and study site.  
d (W)GRS is a categorical variable defined by quartiles of WGRS in controls, e.g. (W)GRS=3 if it is 
above the 75th percentile in controls and (W)GRS=0 if it is below the 25th percentile in controls. 
The minimal, 25th, 50th, 75th percentiles and the maximum are 3, 11, 12, 14 ,22 for GRS and 0.32, 
1.33, 1.53, 1.75 and 2.86 for WGRS. In this table, we only present the coefficient of the interaction 
term corresponding to a change of OCP from 0 to 1 and of WGRS from 0 to 3. 
  
Table 2. Empirical Familywise Type I Error Rate at 5% overall level of significance, and Expected 
Number of False Positives corresponding to UML, CML and EB Wald Tests  
 
 Proportion of markers satisfying gene-environment 
independence (𝑝𝑖𝑛𝑑) 
a 
0.95 0.99 0.995 0.9975 0.9995 1.00 
Empirical Familywise Type I error b 
UML 0.084 0.072 0.062 0.071 0.041 0.058 
CML 1.000 0.994 0.966 0.745 0.874 0.064 
EB 0.138 0.056 0.045 0.038 0.042 0.035 
Expected number of false positives c 
UML 0.085 0.073 0.062 0.071 0.042 0.059 
CML 23.451 3.761 2.814 1.050 0.937 0.067 
EB 0.150 0.060 0.045 0.039 0.044 0.035 
 
Abbreviations: CML, constrained maximum-likelihood; EB, empirical Bayes; RERI, relative excess 
risk due to interaction; UML, unconstrained maximum-likelihood. 
a The population-level G-E association structure among null loci is assumed to be of the form of 
a mixture distribution reflecting that a large fraction, i.e., pind , of the SNPs, indeed, are 
independent of E in the population, whereas the remaining (1 − 𝑝𝑖𝑛𝑑)  of SNPs show some 
departures from the independence assumption following a N (0, sd=log(1.5)/2) distribution. 
b  The Wald test is for RERI=0 under a large-scale genomewide G x E scan simulation scenario 
with 10000 markers and 2000 cases and controls. Empirical familywise type I error is estimated 
as the empirical proportion of data sets declaring at least 1 null marker to be significant using 
level of significance α/10000.  This estimates the probability of at least one false positive under 
the global null.  
c Expected number of false positives is estimated as the average number of falsely rejected null 
hypotheses, averaged over 1000 data sets. 
 
 
  
Figure 1. Odds ratio of oral contraceptive pill and corresponding 95% CI within each quartile of 
the weighted genetic risk score. The odds ratios are estimated from a standard logistic 
regression adjusting for history of endometriosis, first degree family history of ovarian cancer, 
parity, tubal ligation, age and study site. 
 
Figure 2. Predicted probability of ovarian cancer and corresponding 95% CI within each quartile 
of the weighted genetic risk score comparing oral contraceptive pill users and non-users. The 
relative risk parameters are obtained from a standard logistic regression model adjusting for 
history of endometriosis, first degree family history of ovarian cancer, parity, tubal ligation, age 
and study site. We assume that approximately 1.3 percent of women will be diagnosed with 
ovarian cancer at some point during their lifetime and 70% women will use oral contraceptive 
pill at some point in their life. The predicted probabilities are estimated by fixing other covariates 
at their most frequent value. 
Figure 3. Power curves of unconstrained maximum-likelihood (UML), constrained maximum-
likelihood (CML) and empirical Bayes (EB) Wald test for relative excess risk due to interaction 
(RERI) under different strength of G-E association:  data are generated on 4000 cases and 4000 
controls with fixed parameters 𝑝𝐺 = 0.2, 𝑝𝐸 = 0.3, 𝑂𝑅𝐺 = 1.2, 𝑂𝑅𝐸 = 1.5. RERI changes from 0 
to 1.5 with a grid level of 0.1, corresponding multiplicative interaction changes from 0.94 to 1.78. 
The top panels (A, B, C) correspond to the raw power, whereas the bottom panels (D, E, F) 
correspond to the power at empirical 𝛼. The left, center, and right panels correspond to different 
values of the G-E association odds ratio, i.e. exp(𝜃𝐺𝐸)=0.8, 1.0, 1.2. 
 
1 
 
Web Appendix 1. Data for an Unmatched Case-control Study with a Dichotomous Genetic 
Factor and a Dichotomous Environmental Exposure 
 G=0 G=1  
 E=0 E=1 E=0 E=1  
D=0 𝑟01 𝑟02 𝑟03 𝑟04 𝑁0 
D=1 𝑟11 𝑟12 𝑟13 𝑟14 𝑁1 
 
Recall that  𝒓𝟎~ Multinomial (𝑁0, 𝒑𝟎)  and 𝒓𝟏~ Multinomial (𝑁1, 𝒑𝟏) , hence the estimate of 
variance matrix of 𝒓𝟎 is  
?̂?0 = [
𝑟01(𝑁0 − 𝑟01)
−𝑟01𝑟02
−𝑟01𝑟03
−𝑟01𝑟04
−𝑟01𝑟02
𝑟02(𝑁0 − 𝑟02)
−𝑟02𝑟03
−𝑟02𝑟04
−𝑟01𝑟03
−𝑟02𝑟03
𝑟03(𝑁0 − 𝑟03)
−𝑟03𝑟04
−𝑟01𝑟04
−𝑟02𝑟04
−𝑟03𝑟04
𝑟04(𝑁0 − 𝑟04)
] /𝑁0 
Similarly, the estimate of variance matrix of 𝒓𝟏 is  
?̂?1 = [
𝑟11(𝑁1 − 𝑟11)
−𝑟11𝑟12
−𝑟11𝑟13
−𝑟11𝑟14
−𝑟11𝑟12
𝑟12(𝑁1 − 𝑟12)
−𝑟12𝑟13
−𝑟12𝑟14
−𝑟11𝑟13
−𝑟12𝑟13
𝑟13(𝑁1 − 𝑟13)
−𝑟13𝑟14
−𝑟11𝑟14
−𝑟12𝑟14
−𝑟13𝑟14
𝑟14(𝑁1 − 𝑟14)
] /𝑁1 
And 𝒓𝟎 and 𝒓𝟏 are independent. 
 
Web Appendix 2. Variance of the UML estimator 
RERÎuml =
𝑟01𝑟14
𝑟11𝑟04
−
𝑟01𝑟13
𝑟11𝑟03
−
𝑟01𝑟12
𝑟11𝑟02
+ 1 = 𝑓𝑈𝑀𝐿(𝒓𝟎, 𝒓𝟏) 
𝑉𝑎?̂?(RERÎuml) = (
𝜕𝑓𝑈𝑀𝐿
𝜕 𝒓𝟎
)
𝑇
?̂?0 (
𝜕𝑓𝑈𝑀𝐿
𝜕 𝒓𝟎
) + (
𝜕𝑓𝑈𝑀𝐿
𝜕 𝒓𝟏
)
𝑇
?̂?1 (
𝜕𝑓𝑈𝑀𝐿
𝜕 𝒓𝟏
) 
Note that, 
𝜕𝑓𝑈𝑀𝐿
𝜕 𝒓𝟎
=
𝑟01
𝑟11
[
𝐴
𝑟01
,
𝑟12
𝑟02
2 ,
𝑟13
𝑟03
2 , −
𝑟14
𝑟04
2 ]
𝑇
𝑎𝑛𝑑 
𝜕𝑓𝑈𝑀𝐿
𝜕 𝒓𝟏
= −
𝑟01
𝑟11
[
𝐴
𝑟11
,
1
𝑟02
,
1
𝑟03
, −
1
𝑟04
]
𝑇
, 
 𝑤ℎ𝑒𝑟𝑒 𝐴 =
𝑟14
𝑟04
−
𝑟13
𝑟03
−
𝑟12
𝑟02
 . 
2 
 
Using the fact that 𝑟01 + 𝑟02 + 𝑟03 + 𝑟04 = 𝑁0  and 𝑟11 + 𝑟12 + 𝑟13 + 𝑟14 = 𝑁1, we can simplify 
the variance expressions further and obtain 
(
𝜕𝑓𝑈𝑀𝐿
𝜕 𝒓𝟎
)
𝑇
?̂?0 (
𝜕𝑓𝑈𝑀𝐿
𝜕 𝒓𝟎
) = (
𝑟01
𝑟11
)
2
(
𝐴2
𝑟01
+
𝑟12
2
𝑟02
3 +
𝑟13
2
𝑟03
3 +
𝑟14
2
𝑟04
3 ) 
(
𝜕𝑓𝑈𝑀𝐿
𝜕 𝒓𝟏
)
𝑇
?̂?1 (
𝜕𝑓𝑈𝑀𝐿
𝜕 𝒓𝟏
) = (
𝑟01
𝑟11
)
2
(
𝐴2
𝑟11
+
𝑟12
𝑟02
2 +
𝑟13
𝑟03
2 +
𝑟14
𝑟04
2 ). 
Hence,  
𝑉𝑎?̂?(RERÎuml) = (
𝑟01
𝑟11
)
2
[(
1
𝑟01
+
1
𝑟11
)𝐴2 +
𝑟12
2
𝑟02
3 +
𝑟13
2
𝑟03
3 +
𝑟14
2
𝑟04
3 +
𝑟12
𝑟02
2 +
𝑟13
𝑟03
2 +
𝑟14
𝑟04
2 ] 
 
Web Appendix 3. Variance of the CML estimator 
RERÎcml =
(𝑟01 + 𝑟03)(𝑟01 + 𝑟02)𝑟14
(𝑟02 + 𝑟04)(𝑟03 + 𝑟04)𝑟11
−
(𝑟01 + 𝑟02)𝑟13
(𝑟03 + 𝑟04)𝑟11
−
(𝑟01 + 𝑟03)𝑟12
(𝑟02 + 𝑟04)𝑟11
+ 1 
Let 𝑟𝐺 = 𝑟03 + 𝑟04, 𝑟𝐸 = 𝑟02 + 𝑟04, then one can rewrite RERÎcml as, 
RERÎcml =
𝑟14(𝑁0 − 𝑟𝐸)(𝑁0 − 𝑟𝐺)
𝑟11𝑟𝐸𝑟𝐺
−
𝑟13(𝑁0 − 𝑟𝐺)
𝑟11𝑟𝐺
−
𝑟12(𝑁0 − 𝑟𝐸)
𝑟11𝑟𝐸
+ 1 = 𝑓𝐶𝑀𝐿(𝒓𝟎
∗ , 𝒓𝟏) 
 𝑤ℎ𝑒𝑟𝑒 𝒓𝟎
∗ = (𝑟𝐺 , 𝑟𝐸)
𝑇 
𝑟𝐺 , 𝑟𝐸  follow a binomial distribution 𝐵𝑖𝑛(𝑁0, 𝑝03 + 𝑝04) and 𝐵𝑖𝑛(𝑁0, 𝑝02 + 𝑝04). So 𝑉𝑎?̂?(𝑟𝐺) =
𝑟𝐺(𝑁0 − 𝑟𝐺)/𝑁0, 𝑉𝑎?̂?(𝑟𝐸) = 𝑟𝐸(𝑁0 − 𝑟𝐸)/𝑁0  𝑎𝑛𝑑 𝐶𝑜?̂?(𝑟𝐺 , 𝑟𝐸) = 𝐶𝑜?̂?(𝑟03 + 𝑟04, 𝑟02 + 𝑟04) =
𝐶𝑜?̂?(𝑟02, 𝑟03) + 𝐶𝑜?̂?(𝑟03, 𝑟04) + 𝐶𝑜?̂?(𝑟02, 𝑟04) + 𝑉𝑎?̂?(𝑟04) = (𝑟01𝑟04 − 𝑟02𝑟03)/𝑁0 = 𝐵/𝑁0.  
 
𝑉𝑎?̂?(RERÎcml) = (
𝜕𝑓𝐶𝑀𝐿
𝜕 𝒓𝟎
∗ )
𝑇
?̂?0
∗ (
𝜕𝑓𝐶𝑀𝐿
𝜕 𝒓𝟎
∗ ) + (
𝜕𝑓𝐶𝑀𝐿
𝜕 𝒓𝟏
)
𝑇
?̂?1 (
𝜕𝑓𝐶𝑀𝐿
𝜕 𝒓𝟏
),  
𝑤ℎ𝑒𝑟𝑒 (
𝜕𝑓𝐶𝑀𝐿
𝜕 𝒓𝟎
∗ )
𝑇
?̂?0
∗ (
𝜕𝑓𝐶𝑀𝐿
𝜕 𝒓𝟎
∗ ) =
𝑁0
𝑟11
2
[2𝐵𝐶𝐷 + 𝑟𝐺(𝑁0 − 𝑟𝐺)𝐶
2 + 𝑟𝐸(𝑁0 − 𝑟𝐸)𝐷
2] 
𝐶 = 𝑟13 − 𝑟14
𝑁0 − 𝑟𝐸
𝑟𝐸
, 𝐷 = 𝑟12 − 𝑟14
𝑁0 − 𝑟𝐺
𝑟𝐺
 𝑎𝑛𝑑 
𝜕𝑓𝐶𝑀𝐿
𝜕 𝒓𝟏
= [
𝐹
𝑟11
, −
𝑁0 − 𝑟𝐸
 𝑟11𝑟𝐸
 , −
𝑁0 − 𝑟𝐺
 𝑟11𝑟𝐺
,   
3 
 
(𝑁0 − 𝑟𝐸)(𝑁0 − 𝑟𝐺)
𝑟11𝑟𝐸𝑟𝐺
]𝑇 , 𝐹 = 𝑟12
𝑁0 − 𝑟𝐸
𝑟𝐸
+ 𝑟13
𝑁0 − 𝑟𝐺
𝑟𝐺
− 𝑟14
(𝑁0 − 𝑟𝐺)(𝑁0 − 𝑟𝐸)
𝑟𝐺𝑟𝐸
, (
𝜕𝑓𝐶𝑀𝐿
𝜕 𝒓𝟏
)
𝑇
?̂?1 
(
𝜕𝑓𝐶𝑀𝐿
𝜕 𝒓𝟏
) =
1
𝑟11
2 [
𝐹2
𝑟11
+ 𝑟12 (
𝑁0 − 𝑟𝐸
𝑟𝐸
)
2
+ 𝑟13 (
𝑁0 − 𝑟𝐺
𝑟𝐺
)
2
+ 𝑟14 (
(𝑁0 − 𝑟𝐺)(𝑁0 − 𝑟𝐸)
𝑟𝐺𝑟𝐸
)
2
] . 
Hence, 
𝑉𝑎?̂?(RERÎcml) =
𝑁0
𝑟11
2
[2𝐵𝐶𝐷 + 𝑟𝐺(𝑁0 − 𝑟𝐺)𝐶
2 + 𝑟𝐸(𝑁0 − 𝑟𝐸)𝐷
2] +
1
r11
2 [
F2
r11
+ 𝑟12 (
𝑁0 − 𝑟𝐸
𝑟𝐸
)
2
 
+𝑟13 (
𝑁0 − 𝑟𝐺
𝑟𝐺
)
2
+ 𝑟14 (
(𝑁0 − 𝑟𝐺)(𝑁0 − 𝑟𝐸)
𝑟𝐺𝑟𝐸
)
2
] 
 
Web Appendix 4. Variance of the EB estimator 
𝑅𝐸𝑅?̂?𝐸𝐵 =
(𝑅𝐸𝑅?̂?𝑢𝑚𝑙 − 𝑅𝐸𝑅?̂?𝑐𝑚𝑙)
2
𝑉𝑎?̂?𝑢𝑚𝑙 + (𝑅𝐸𝑅?̂?𝑢𝑚𝑙 − 𝑅𝐸𝑅?̂?𝑐𝑚𝑙)
2 𝑅𝐸𝑅?̂?𝑢𝑚𝑙 +
𝑉𝑎?̂?𝑢𝑚𝑙
𝑉𝑎?̂?𝑢𝑚𝑙 + (𝑅𝐸𝑅?̂?𝑢𝑚𝑙 − 𝑅𝐸𝑅?̂?𝑐𝑚𝑙)
2 𝑅𝐸𝑅?̂?𝑐𝑚𝑙  
Here we consider 𝑉𝑎?̂?𝑢𝑚𝑙  as a constant, then 𝑅𝐸𝑅?̂?𝐸𝐵  is a function of 𝑅𝐸𝑅?̂?𝑢𝑚𝑙 and 𝑅𝐸𝑅?̂?𝑐𝑚𝑙 . 
Again, we apply delta method to derive the corresponding variance. 
 
𝑉𝑎?̂?(RERÎEB) = 𝑉𝑎𝑟(𝑓(RERÎuml,RERÎcml ))
= [
𝜕RERÎEB
𝜕RERÎuml
𝜕RERÎEB
𝜕RERÎcml
] [
𝑉𝑎?̂?(RERÎuml) Cov̂(RERÎuml, RERÎcml)
Cov̂(RERÎuml, RERÎcml) 𝑉𝑎?̂?(RERÎcml)
]
[
 
 
 
 
𝜕RERÎEB
𝜕RERÎuml
𝜕RERÎEB
𝜕RERÎcml]
 
 
 
 
 
= 𝑎2𝑉𝑎?̂?(RERÎuml) + 𝑏
2𝑉𝑎?̂?(RERÎcml) + 2𝑎𝑏Cov̂(RERÎuml, RERÎcml) 
𝑤ℎ𝑒𝑟𝑒 𝑎 =
𝜕RERÎEB
𝜕RERÎuml
=
3RERÎuml
2 − 4RERÎumlRERÎcml + RERÎcml
2
𝑉𝑎?̂?(RERÎuml) + (RERÎuml − RERÎuml)
2 − 
2𝑉𝑎?̂?(RERÎuml)RERÎcml(RERÎuml − RERÎcml) + 2RERÎuml(RERÎuml − RERÎcml)
3
(𝑉𝑎?̂?(RERÎuml) + (RERÎuml − RERÎuml)
2
)
2   
4 
 
𝑏 =
𝜕RERÎEB
𝜕RERÎcml
=
𝑉𝑎?̂?(RERÎuml)
2
− 𝑉𝑎?̂?(RERÎuml)(RERÎuml − RERÎuml)
2
(𝑉𝑎?̂?(RERÎuml) + (RERÎuml − RERÎuml)
2
)
2  
 
And by using similar argument, 
Cov̂(RERÎuml, RERÎcml) = (
𝜕𝑓𝑈𝑀𝐿
𝜕 𝒓𝟎
)
𝑇
?̂?0 (
𝜕𝑓𝐶𝑀𝐿
𝜕 𝒓𝟎
) + (
𝜕𝑓𝑈𝑀𝐿
𝜕 𝒓𝟏
)
𝑇
?̂?1 (
𝜕𝑓𝐶𝑀𝐿
𝜕 𝒓𝟏
) 
𝜕𝑓𝑈𝑀𝐿
𝜕 𝒓𝟎
,
𝜕𝑓𝑈𝑀𝐿
𝜕 𝒓𝟏
 and 
𝜕𝑓𝐶𝑀𝐿
𝜕 𝒓𝟏
 are already calculated in previous derivation, substituting 
 
𝜕𝑓𝐶𝑀𝐿
𝜕 𝒓𝟎
=
[𝐻, 𝐼, 𝐽, 𝐾]𝑇
𝑟11
, 𝑤ℎ𝑒𝑟𝑒 𝐻 =
𝑟14(2𝑁0 − 𝑟𝐺 − 𝑟𝐸)
𝑟𝐺𝑟𝐸
−
𝑟13
𝑟𝐺
−
𝑟12
𝑟𝐸
, 𝐼 = 𝑟12
𝑁0 − 𝑟𝐸
𝑟𝐸
2 −
𝑟13
𝑟𝐺
+ 
𝑟14
(𝑁0 − 𝑟𝐸)(𝑟04 − 𝑟01)
𝑟𝐸
2𝑟𝐺
, 𝐽 = 𝑟13
𝑁0 − 𝑟𝐺
𝑟𝐺
2 −
𝑟12
𝑟𝐸
+ 𝑟14
(𝑁0 − 𝑟𝐺)(𝑟04 − 𝑟01)
𝑟𝐺
2𝑟𝐸
 and  
𝐾 = 𝑟12
𝑁0 − 𝑟𝐸
𝑟𝐸
2 + 𝑟13
𝑁0 − 𝑟𝐺
𝑟𝐺
2 − 𝑟14
(𝑁0 − 𝑟𝐺)(𝑁0 − 𝑟𝐸)
𝑟𝐺
2𝑟𝐸
− 𝑟14
(𝑁0 − 𝑟𝐺)(𝑁0 − 𝑟𝐸)
𝑟𝐸
2𝑟𝐺
 
 
Finally, we obtain the covariance  
Cov̂(RERÎuml, RERÎcml) =
r01
𝑟11
2 [𝐴𝐻 +
𝑟12
𝑟02
𝐼 +
𝑟13
𝑟03
𝐽 −
𝑟14
𝑟04
𝐾 −
𝐴𝐹
𝑟11
+
𝑟12
 𝑟02
𝑁0 − 𝑟𝐸
𝑟𝐸
+ 
𝑟13
𝑟03
𝑁0−𝑟𝐺
𝑟𝐺
+
𝑟14
𝑟04
(𝑁0−𝑟𝐺)(𝑁0−𝑟𝐸)
𝑟𝐺𝑟𝐸
] 
 
Web Appendix 5. Estimated and Empirical Variance of Three Estimators 
Although, theoretically Delta method doesn’t apply under G-E independence, practically, the 
estimated variance from delta method approximate the simulation results very well. Hence we 
consider both CML and EB estimators are ready to use. We illustrate this point by a similar 
simulation to the power analysis one in the paper. We set p(G)=0.2, p(E)=0.3, OR(G)=1.2, 
OR(E)=1.5, number of cases and controls are both 2000. We change the true values of RERI from 
5 
 
-0.3 to 0.3 and exp(θGE) from 0.9 to 1.1 with a grid of 0.05. Then we calculate the empirical 
variance of estimated RERI and the average of estimated variance by the proposed method across 
5,000 datasets. The Web Table 1 shows the two variances of three estimators. The empirical 
variance of EB deviates a little from the variance obtained by formula because we consider 
𝑉𝑎?̂?(𝑅𝐸𝑅?̂?𝑢𝑚𝑙) as a constant in the derivation. 
 
Given the fact that the estimated variance is close to the empirical variance, we then numerically 
evaluated the distribution of the test statistics corresponding to CML and EB to a reference 
normal distribution under large sample size. In this situation, we set the numbers of cases and 
controls to be 5000, and additionally fix RERI=0 and exp(𝜃𝐺𝐸) = exp (
1
√𝑁0+𝑁1
) = exp (0.01), 
which is the contiguous departure from the independence assumption that you have indicated 
in your comment. We evaluate the empirical distribution of CML and EB test statistics over 5,000 
simulation replications (See Web Figure 1). Shapiro-Wilk tests do not reject the null hypothesis 
that the distributions of CML and EB are normal with p=0.607 and p=0.307, respectively. The QQ 
plots of the empirical quantile and theoretical standard normal quantile also indicate strong 
agreement (See Web Figure 2). Additionally, we calculate the empirical MSE under different  𝜃𝐺𝐸  
of order 𝑁−
1
𝑘 with k=2,3,4,5 using the same setting (See Web Table 2).  
 
  
6 
 
Web Table 1. Comparison of Proposed Variance Formula and Empirical Variance 
RERI exp(θGE) UML1* UML2* CML1* CML2* EB1* EB2* 
 
 
-0.3 
0.90 0.0555 0.0550 0.0249 0.0238 0.0445 0.0416 
0.95 0.0546 0.0542 0.0248 0.0240 0.0398 0.0361 
1.00 0.0537 0.0541 0.0248 0.0244 0.0377 0.0348 
1.05 0.0533 0.0538 0.0249 0.0251 0.0383 0.0360 
1.10 0.0526 0.0544 0.0250 0.0254 0.0404 0.0393 
 
 
0.3 
0.90 0.0798 0.0813 0.0316 0.0321 0.0639 0.0603 
0.95 0.0780 0.0774 0.0323 0.0320 0.0561 0.0518 
1.00 0.0762 0.0733 0.0329 0.0324 0.0524 0.0480 
1.05 0.0749 0.0764 0.0336 0.0342 0.0528 0.0499 
1.10 0.0739 0.0759 0.0345 0.0352 0.0563 0.0545 
*1 denotes the average of 5000 estimated variances by proposed formula and 2 denotes the 
empirical variance of 5000 point estimates. 
 
 
Web Table 2. MSE of UML, CML and EB estimators over 5000 replications with different choices 
of θGE 
 
𝜃𝐺𝐸 ∝ 𝑁
−
1
𝑘 UML CML EB 
k=2 0.0255 0.0113 0.0159 
k=3 0.0245 0.0162 0.0176 
k=4 0.0244 0.0348 0.0236 
k=5 0.0237 0.0694 0.0280 
 
 
 
  
7 
 
Web Figure 1: Density of CML and EB Test Statistics 
 
 
Web Figure 2: QQ Plots of CML and EB Test Statistics  
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Web Appendix 6. UML, CML and EB Estimators in General Cases 
𝑅𝐸𝑅𝐼(𝐸0, 𝐸1, 𝐺0, 𝐺1) 
≈ exp{𝛽𝐺(𝐺1 − 𝐺0) + 𝛽𝐸(𝐸1 − 𝐸0) + 𝛽𝐺𝐸(𝐺1×𝐸1 − 𝐺0×𝐸0)}
− exp{𝛽𝐸(𝐸1 − 𝐸0) + 𝛽𝐺𝐸𝐺0×(𝐸1 − 𝐸0)}
− exp{𝛽𝐺(𝐺1 − 𝐺0) + 𝛽𝐺𝐸(𝐺1 − 𝐺0)×𝐸0} + 1 
= 𝑓(𝛽𝐺 , 𝛽𝐸 , 𝛽𝐺𝐸 ) 
 
So 𝑅𝐸𝑅𝐼(𝐸0, 𝐸1, 𝐺0, 𝐺1) is a function of 𝛽𝐺 , 𝛽𝐸 , 𝛽𝐺𝐸  given 𝐸0, 𝐸1, 𝐺0, 𝐺1. The derivatives of RERI 
with respect to 𝛽𝐺 , 𝛽𝐸 , 𝛽𝐺𝐸 are 
𝑓𝐺
′ =
∂𝑅𝐸𝑅𝐼
∂𝛽𝐺
= [exp{𝛽𝐺(𝐺1 − 𝐺0) + 𝛽𝐸(𝐸1 − 𝐸0) + 𝛽𝐺𝐸(𝐺1×𝐸1 − 𝐺0×𝐸0)}
− exp{𝛽𝐺(𝐺1 − 𝐺0) + 𝛽𝐺𝐸(𝐺1 − 𝐺0)×𝐸0}](𝐺1 − 𝐺0) 
𝑓𝐸
′ =
∂𝑅𝐸𝑅𝐼
∂𝛽𝐸
= [exp{𝛽𝐺(𝐺1 − 𝐺0) + 𝛽𝐸(𝐸1 − 𝐸0) + 𝛽𝐺𝐸(𝐺1×𝐸1 − 𝐺0×𝐸0)}
− exp{𝛽𝐸(𝐸1 − 𝐸0) + 𝛽𝐺𝐸𝐺0×(𝐸1 − 𝐸0)}](𝐸1 − 𝐸0) 
𝑓𝐺𝐸
′ =
∂𝑅𝐸𝑅𝐼
∂𝛽𝐺𝐸
= exp{𝛽𝐺(𝐺1 − 𝐺0) + 𝛽𝐸(𝐸1 − 𝐸0) + 𝛽𝐺𝐸(𝐺1×𝐸1 − 𝐺0×𝐸0)} (𝐺1×𝐸1 − 𝐺0×𝐸0)
− exp{𝛽𝐸(𝐸1 − 𝐸0) + 𝛽𝐺𝐸𝐺0×(𝐸1 − 𝐸0)}𝐺0×(𝐸1 − 𝐸0)
− exp{𝛽𝐺(𝐺1 − 𝐺0) + 𝛽𝐺𝐸(𝐺1 − 𝐺0)×𝐸0}(𝐺1 − 𝐺0)×𝐸0 
 
More generally, if G or E is a factor with different coefficients for different levels, then RERI has 
the form below: 
𝑅𝐸𝑅𝐼(𝐸0, 𝐸1, 𝐺0, 𝐺1) 
=
exp(𝛽𝐺1 + 𝛽𝐸1 + 𝛽𝐺1𝐸1) − exp(𝛽𝐺1 + 𝛽𝐸0 + 𝛽𝐺1𝐸0) − exp(𝛽𝐺0 + 𝛽𝐸1 + 𝛽𝐺0𝐸1) + exp(𝛽𝐺0 + 𝛽𝐸0 + 𝛽𝐺0𝐸0)
exp(𝛽𝐺0 + 𝛽𝐸0 + 𝛽𝐺0𝐸0)
 
= exp{(𝛽𝐺1 − 𝛽𝐺0) + (𝛽𝐸1 − 𝛽𝐸0) + (𝛽𝐺1𝐸1 − 𝛽𝐺0𝐸0)} − exp{(𝛽𝐺1 − 𝛽𝐺0) + (𝛽𝐺1𝐸0 − 𝛽𝐺0𝐸0)}
+ exp{(𝛽𝐸1 − 𝛽𝐸0) + (𝛽𝐺0𝐸1 − 𝛽𝐺0𝐸0)} + 1 
= 𝑓(𝛽𝐺 , 𝛽𝐸 , 𝛽𝐺𝐸 ) 
If any of 𝛽s with subscript 0 corresponds to the reference group in the model, then we set it to 
zero. The derivatives of RERI in this situation is similar to those derived above but with 𝛽, 𝐺, 𝐸, 𝐺𝐸 
as vectors instead of scalars. For example, if G is coded as 0-1-2 with 0 as reference group, then 
(𝛽𝐺2 − 𝛽𝐺1) can be expressed as 𝛽𝐺(𝐺2 − 𝐺1) = (𝛽𝐺1, 𝛽𝐺2)[(0,1) − (1,0)]
𝑇 and (𝛽𝐺2 − 𝛽𝐺0) can 
be expressed as (𝛽𝐺1, 𝛽𝐺2)[(0,1) − (0,0)]
𝑇. 
 
According to Mukherjee and Chatterjee (6), the joint distribution of the MLE (?̂?𝒖𝒎𝒍, ?̂?𝒄𝒎𝒍) is 
asymptotically multivariate normal. The variance-covariance matrix can be estimated from 
“CGEN” package and it has the form below. 
𝑉𝑎𝑟 (?̂?𝒖𝒎𝒍, ?̂?𝒄𝒎𝒍) = [
𝑽𝟏 𝚺
𝚺 𝑽𝟐
] 
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where ?̂?𝒖𝒎𝒍, ?̂?𝒄𝒎𝒍 are both k × 1 vectors and 𝑽𝟏, 𝑽𝟐, 𝚺 are k × k matrices, where k is the number 
of coefficients of (𝛽𝐺 , 𝛽𝐸 , 𝛽𝐺𝐸 ) in the logistic regression disease risk model. By applying Delta 
method, we obtain 
 
(a) The variance of UML estimator of RERI is 𝐵1
𝑇𝑉1𝐵1 , where 𝐵1  is the derivative vector of 
𝑅𝐸𝑅𝐼𝑢𝑚𝑙. 
(b) The variance of CML estimator of RERI is 𝐵0
𝑇𝑉0𝐵0 , where 𝐵0  is the derivative vector of 
𝑅𝐸𝑅𝐼𝑐𝑚𝑙. 
(c) The EB estimator of RERI is 
(𝑅𝐸𝑅?̂?𝑢𝑚𝑙 − 𝑅𝐸𝑅?̂?𝑐𝑚𝑙)
2
(𝑅𝐸𝑅?̂?𝑢𝑚𝑙 − 𝑅𝐸𝑅?̂?𝑐𝑚𝑙)2 + 𝐵1
𝑇𝑉1𝐵1
𝑅𝐸𝑅?̂?𝑢𝑚𝑙 +
𝐵1
𝑇𝑉1𝐵1
(𝑅𝐸𝑅?̂?𝑢𝑚𝑙 − 𝑅𝐸𝑅?̂?𝑐𝑚𝑙)2 + 𝐵1
𝑇𝑉1𝐵1
𝑅𝐸𝑅?̂?𝑐𝑚𝑙  
 
Note that ∂𝑅𝐸𝑅?̂?𝐸𝐵  is a function of  𝑅𝐸𝑅?̂?𝑢𝑚𝑙  and 𝑅𝐸𝑅?̂?𝑐𝑚𝑙 . Let 𝑅1  denote 𝑅𝐸𝑅?̂?𝑢𝑚𝑙  and 𝑅0 
denote 𝑅𝐸𝑅?̂?𝑐𝑚𝑙. 
∂𝑅𝐸𝑅?̂?𝐸𝐵
∂𝑅1
=
3𝑅1
2 − 4𝑅1𝑅0 + 𝑅0
2
𝐵1
𝑇𝑉1𝐵1 + (𝑅1 − 𝑅0)2
− 2
𝐵1
𝑇𝑉1𝐵1𝑅0(𝑅1 − 𝑅0) + 𝑅1(𝑅1 − 𝑅0)
3
[𝐵1
𝑇𝑉1𝐵1 + (𝑅1 − 𝑅0)2]2
,  
∂𝑅𝐸𝑅?̂?𝐸𝐵
∂𝑅0
=
(𝐵1
𝑇𝑉1𝐵1)
2 − 𝐵1
𝑇𝑉1𝐵1(𝑅1 − 𝑅0)
2
[𝐵1
𝑇𝑉1𝐵1 + (𝑅1 − 𝑅0)2]2
  
Cov(𝑅𝐸𝑅?̂?𝑢𝑚𝑙, 𝑅𝐸𝑅?̂?𝑐𝑚𝑙) = 𝐶𝑜𝑣 (𝑓(?̂?𝒖𝒎𝒍), 𝑓(?̂?𝒄𝒎𝒍))
= [
∂𝑓(?̂?𝒖𝒎𝒍)
∂?̂?𝒖𝒎𝒍
]
𝑇
𝐶𝑜𝑣(?̂?𝒖𝒎𝒍, ?̂?𝒄𝒎𝒍)
∂𝑓(?̂?𝒄𝒎𝒍)
∂?̂?𝒄𝒎𝒍
= 𝐵1
𝑇 𝛴𝐵0 
Hence, the variance of 𝑅𝐸𝑅?̂?𝐸𝐵 is 𝐴
𝑇 [
𝐵1
𝑇𝑉1𝐵1 𝐵1
𝑇 𝛴𝐵0
𝐵1
𝑇 𝛴𝐵0 𝐵0
𝑇𝑉0𝐵0
] 𝐴, where 𝐴𝑇 = [
∂𝑅𝐸𝑅?̂?𝐸𝐵
∂𝑅1
,
∂𝑅𝐸𝑅?̂?𝐸𝐵
∂𝑅0
 ].The 
Wald test is still based on standardized Z statistic. 
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Web Table 3. Odds Ratios for Marginal Associations of 18 Susceptibility Variants with Ovarian 
Cancer Risk from Previous Studies 
 
SNP Chromosome Position 
Reference 
Allele(s) 
Tested 
Allele 
Tested 
Allele 
Frequency 
Published ORa 
95% CI 
rs58722170 1p34.3 38096421 G C 0.22 1.07 (1.03, 1.11) 
rs10069690 5p15.33 1279790 C T 0.26 1.09 (1.05, 1.13) 
chr10:21878831:D 10p12.31 21878831 allele1 T 0.30 1.09 (1.06, 1.13) 
rs17329882 4q26 119949960 A C 0.24 1.09 (1.06, 1.13) 
rs1879586 17q21.31 43567337 C G 0.17 1.13 (1.09, 1.18) 
rs56318008 1p36 22470407 C T 0.15 1.11 (1.06, 1.15) 
rs4808075 19p13.11 17390291 T C 0.30 1.12 (1.09, 1.16) 
chr9:136138765:D 9q34.2 136138765 allele2 G 0.15 1.15 (1.10, 1.20) 
rs7207826 17q21.32 46500673 T C 0.27 1.13 (1.09,1.16) 
rs76837345 8q21.13 82668818 A G 0.07 1.20 (1.13, 1.27) 
rs62274042 3q25.31 156435952 G A 0.05 1.45 (1.37,1.54) 
rs635634 9q34.2 136155000 C T 0.20 1.12 (1.08, 1.16) 
rs3744763 17q12 36090885 A G 0.59 1.06 (1.03, 1.09) 
chr17:29181220:I 17q11.2 29181220 AT A 0.72 1.11 (1.07, 1.15) 
rs6755777 2q31.1 177043326 G T 0.32 1.13 (1.09,1.16) 
rs1400482 8q24.21 129541931 A G 0.87 1.18 (1.13,1.23) 
rs116133110 6q22.1 28480635 C T 0.69 1.07 (1.03, 1.10) 
rs10962691 
(rs117224476)b 
9q22.2 16915105 G C 0.79 1.25 (1.20, 1.30) 
 
Abbreviations: allele1, TCCCTTC; allele2, GCGCCCACCACTA. 
a ORs are obtained from analysis in Collaborative Oncological Gene-Environment Study (COGS) 
(26-33). 
b rs117224476 was the strongest hit in previous studies, however, it was not genotyped in 
current study. rs10962691 is the closest proxy of this SNP. 
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Web Table 4. Odds Ratios for Marginal Associations of Categorical GRS and WGRS in Subjects 
with European Ancestry with 4,135 Cases and 7,526 Controls from 13 Sites 
 
Risk Score Categories OR 95% CI P value 
GRS [1]a Ref   
GRS [2] 1.14b (1.01,1.29) 3.56×10-2 
GRS [3] 1.32 (1.19,1.46) 8.48×10-8 
GRS [4] 1.90 (1.71,2.10) 2.95×10-33 
WGRS [1]a Ref   
WGRS [2] 1.20c (1.07,1.36) 2.13×10-3 
WGRS [3] 1.38 (1.23,1.55) 4.76×10-8 
WGRS [4] 1.97 (1.76,2.20) 9.04×10-33 
 
Abbreviations: GRS, genetic risk score; WGRS, weighted genetic risk score; Ref, reference group. 
a GRS [k] and WGRS [k] denote the kth category of the corresponding risk score in controls. The 
0%,25%, 50%, 75% and 100% percentiles are 3, 11, 12, 14, 22 for GRS; 0.32, 1.33, 1.53, 1.75, 
2.86 for WGRS.  
b ORs are estimated from logistic regression models including main effects for GRS/WGRS, 
adjusted for study sites and 26 principal components. 
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Web Table 5: Odds Ratios for Marginal Associations of Seven Environmental Exposures with 
Ovarian Cancer Risk with 7,783 Cases and 13,750 Controls from 15 Sites 
 
Exposure Control Case Unadjusted ORa Adjusted ORb 95 % CI P value 
OC never 4227 3197 Ref Ref    
OC ever 9523 4586 0.64 0.60 0.56 0.64 5.02×10-51 
        
Fullbirths>=1 11623 5783 Ref Ref    
Fullbirths=0 2127 2000 1.89 1.73 1.60 1.87 2.10×10-45 
 
Age        
(69,74) 1283 707 Ref Ref    
(50,54) 1631 1020 1.13 1.39 1.22 1.59 8.76×10-7 
(54,59) 2157 1330 1.12 1.42 1.26 1.61 2.26×10-8 
(59,64) 2038 1207 1.07 1.34 1.18 1.52 4.01×10-6 
(64,69) 1669 950 1.03 1.16 1.02 1.32 2.08×10-2 
<=50 4335 2187 0.92 1.06 0.94 1.19 3.61×10-1 
>74 637 382 1.09 1.06 0.90 1.26 4.75×10-1 
 
Race        
Black 366 196 Ref Ref    
HW 353 260 1.38 1.36 1.05 1.74 1.74×10-2 
NHW 12440 6876 1.03 1.06 0.88 1.28 5.55×10-1 
Asian 314 287 1.71 1.41 1.09 1.82 8.81×10-3 
other 277 164 1.11 1.04 0.78 1.37 8.07×10-1 
        
tublig=Yes 3078 1300 Ref Ref    
tublig=No 10672 6483 1.44 1.39 1.29 1.51 1.62×10-16 
        
endom=No 12915 6966 Ref Ref    
endom=Yes 835 817 1.81 1.64 1.48 1.83 6.30×10-20 
        
famhist=No 13355 7318 Ref Ref    
famhist=Yes 395 465 2.15 2.19 1.90 2.52 6.76×10-27 
 
Abbreviations: endom, history of endometriosis; famhist, family history; Fullbirths, number of 
full-term births; HW, Hispanic White; NHW, Non-Hispanic White; tublig, tubal ligation; Ref, 
reference group.  
a ORs are obtained from univariate logistic regression models, as well as contingency tables. 
b ORs are estimated from logistic regression models including main effects for environmental 
exposures, and adjusted for study sites. 
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Web Table 6: Description of Study Sites Included in the Analysis 
  
Study Name 
Study 
Abbreviation 
Country 
Number 
of 
Cases (E) 
Number of 
Controls 
(E) 
Number of 
Cases 
(G×E) 
Number of 
Controls 
(G×E) 
Australian Ovarian Cancer Study AUS Australia 1037 1383 791 1078 
Connecticut Ovary Study CON USA 357 551 0 0 
Diseases of the Ovary and their Evaluation DOV USA 884 1674 700 1326 
Germany Ovarian Cancer Study GER Germany 175 526 137 374 
Hawaii Ovarian Cancer Study HAW USA 277 407 39 72 
Hormones and Ovarian Cancer Prediction HOP USA 465 1457 328 957 
Danish Malignant Ovarian Tumor Study MAL Denmark 432 1465 236 602 
Mayo Clinic Ovarian Cancer Case Control 
Study 
MAY USA 201 0 177 0 
North Carolina Ovarian Cancer Study NCO USA 689 1003 468 682 
New England-based Case-Control Study of  
Ovarian Cancer 
NEC USA 1187 1763 335 557 
New Jersey Ovarian Cancer Study NJO USA 206 441 0 0 
Nijmegen Polygene Study & Nijmegen  
Biomedical Study 
NTH Netherlands 240 475 231 461 
UC Irvine Ovarian Cancer Study UCI USA 280 263 104 120 
UK Ovarian Cancer Population Study UKO UK 351 731 288 630 
Los Angeles County Case-Control Studies of  
Ovarian Cancer 
USC USA 1002 1611 301 667 
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Web Appendix 7. Equations with respect to Cell Probability 𝒑𝟎 and 𝒑𝟏in Simulation  
exp(𝜃𝐺𝐸) =
𝑝01(𝑝01 + 𝑝𝐺 + 𝑝𝐸 − 1)
(1 − 𝑝𝐺 − 𝑝01)(1 − 𝑝𝐸 − 𝑝01)
 
𝑝02 = 1 − 𝑝𝐺 − 𝑝01,  𝑝03 = 1 − 𝑝𝐸 − 𝑝01,  𝑝04 = 1 − 𝑝01 − 𝑝02 − 𝑝03 
Let 𝑝 = 𝑝01 + 𝑝02𝑂𝑅𝐸 + 𝑝03𝑂𝑅𝐺 + 𝑝04𝑂𝑅𝐺𝐸,  
𝑝11 = 𝑝01/𝑝 ,  𝑝12 = 𝑝02𝑂𝑅𝐸/𝑝 ,  𝑝13 = 𝑝03𝑂𝑅𝐺/𝑝 ,  𝑝14 = 𝑝04𝑂𝑅𝐺𝐸/𝑝 , 
where 𝑂𝑅𝐺𝐸 = 𝑅𝐸𝑅𝐼 + 𝑂𝑅𝐺 + 𝑂𝑅𝐸 − 1 according to equation (3) given RERI, 𝑂𝑅𝐺 and 𝑂𝑅𝐸. 
 
Web Figure 3: Distributions of GRS and WGRS in Cases and Controls in Subjects with European 
Ancestry 
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Web Table 7. Type I Error for Different Estimators of RERI Under Four Sample Size and Test Size 
Settings When pG = 0.2, pE = 0.3, ORG = 1.2, ORE = 1.5 
Setting exp(θGE) 0.8 0.9 1 1.1 1.2 
N=4000a, 
α=0.05 
UML 0.049 0.053 0.048 0.047 0.059 
CML 0.822 0.27 0.053 0.219 0.645 
EB 0.085 0.092 0.049 0.078 0.098 
N=20000, 
α=0.05 
UML 0.056 0.057 0.05 0.051 0.053 
CML 1 0.854 0.051 0.768 1 
EB 0.061 0.086 0.031 0.099 0.075 
N=4000, 
α =5×10-6 
UML 8.00×10-6 7.00×10-6 4.00×10-6 4.00×10-6 3.00×10-6 
CML 4.66×10-2 7.83×10-4 3.00×10-6 1.11×10-4 5.71×10-3 
EB 9.52×10-4 1.42×10-4 1.00×10-6 2.10×10-5 2.36×10-4 
N=20000, 
α =5×10-6 
UML 4.00×10-6 7.00×10-6 2.00×10-6 3.00×10-6 5.00×10-6 
CML 9.66×10-1 6.67×10-2 7.00×10-6 2.72×10-2 7.31×10-1 
EB 1.30×10-5 8.68×10-4 4.00×10-6 6.13×10-4 2.80×10-5 
a N denotes the sample size of cases and controls, 𝑁0 = 𝑁1 = 𝑁. 
 
 
Web Figure 4. Type I error for Wald tests of RERI under different 𝜃𝐺𝐸  when 𝑝𝐺 = 0.3, 𝑝𝐸 =
0.3, 𝑂𝑅𝐺 = 1.2, 𝑂𝑅𝐸 = 1.5, 𝑁 = 4000, 𝛼 = 0.05. 
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Web Table 8: Type I error for UML, CML and EB estimator of RERI 
Fix: 𝑝𝐺 = 0.2, 𝑝𝐸 = 0.3, N0 = 𝑁1 = 4000, α = 0.05 
Vary: 𝑂𝑅𝐸 = (1.3, 1.5, 1.7), 𝑂𝑅𝐺 = (1.1, 1.2, 1.3),  exp(𝜃𝐺𝐸) = (0.8, 1, 1.2)  
 
exp(𝜃𝐺𝐸) 𝑂𝑅𝐸 𝑂𝑅𝐺 UML CML EB  
1.3 1.1 0.056 0.766 0.102 
 1.3 1.2 0.044 0.792 0.090 
 1.3 1.3 0.056 0.822 0.084 
 1.5 1.1 0.056 0.790 0.104 
0.8 1.5 1.2 0.058 0.822 0.098 
 1.5 1.3 0.062 0.832 0.088 
 1.7 1.1 0.064 0.804 0.110 
 1.7 1.2 0.064 0.814 0.112 
 1.7 1.3 0.060 0.834 0.098  
1.3 1.1 0.076 0.040 0.022 
 1.3 1.2 0.056 0.050 0.048 
 1.3 1.3 0.044 0.060 0.046 
 1.5 1.1 0.052 0.048 0.048 
1 1.5 1.2 0.054 0.054 0.046 
 1.5 1.3 0.058 0.046 0.038 
 1.7 1.1 0.058 0.044 0.038 
 1.7 1.2 0.062 0.046 0.040 
 1.7 1.3 0.054 0.044 0.038  
1.3 1.1 0.056 0.624 0.102 
 1.3 1.2 0.064 0.634 0.112 
 1.3 1.3 0.052 0.656 0.104 
 1.5 1.1 0.046 0.632 0.092 
1.2 1.5 1.2 0.066 0.624 0.100 
 1.5 1.3 0.058 0.642 0.118 
 1.7 1.1 0.066 0.632 0.088 
 1.7 1.2 0.070 0.638 0.114 
 1.7 1.3 0.064 0.642 0.096 
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Web Table 9: Type I error for UML, CML and EB estimator of RERI 
Fix: 𝑂𝑅𝐺 = 1.2, 𝑂𝑅𝐸 = 1.5, N0 = 𝑁1 = 4000, α = 0.05 
Vary: 𝑝𝐺 = (0.1, 0.2, 0.3), 𝑝𝐸 = (0.3, 0.4, 0.5),  exp(𝜃𝐺𝐸) = (0.8, 1, 1.2)  
 
exp(𝜃𝐺𝐸) 𝑝𝐺 𝑝𝐸 UML CML EB 
 0.1 0.3 0.048 0.612 0.114 
 0.2 0.3 0.058 0.822 0.098 
 0.3 0.3 0.058 0.890 0.100 
 0.1 0.4 0.046 0.644 0.092 
0.8 0.2 0.4 0.054 0.820 0.076 
 0.3 0.4 0.058 0.900 0.080 
 0.1 0.5 0.042 0.624 0.092 
 0.2 0.5 0.074 0.828 0.090 
 0.3 0.5 0.072 0.896 0.078 
 0.1 0.3 0.042 0.064 0.044 
 0.2 0.3 0.054 0.054 0.046 
 0.3 0.3 0.042 0.064 0.046 
 0.1 0.4 0.064 0.050 0.038 
1 0.2 0.4 0.060 0.082 0.064 
 0.3 0.4 0.062 0.072 0.044 
 0.1 0.5 0.044 0.058 0.044 
 0.2 0.5 0.054 0.052 0.044 
 0.3 0.5 0.076 0.038 0.040 
 0.1 0.3 0.060 0.372 0.090 
 0.2 0.3 0.066 0.624 0.100 
 0.3 0.3 0.064 0.730 0.116 
 0.1 0.4 0.038 0.428 0.082 
1.2 0.2 0.4 0.068 0.658 0.082 
 0.3 0.4 0.054 0.766 0.094 
 0.1 0.5 0.058 0.408 0.106 
 0.2 0.5 0.056 0.632 0.094 
 0.3 0.5 0.050 0.760 0.084 
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Web Appendix 8. Type I Error of EB Test in Large Genomewide Assessment Studies 
To justify the EB estimator in genomewide assessment of GxE, we conduct another simulation 
study similar to that in References (8), which generates 1 significant marker together with M-1 
null markers and the G-E odds ratios in control are different between causal makers and null 
markers. The detailed simulation setting is as below. 
        we consider the situation with 2,000 cases and 2,000 controls with the number of markers 
M =10,000. The prevalence of binary E is 0.5 throughout. All main effect parameters are assumed 
to be unity, namely, 𝑂𝑅𝐺 = 𝑂𝑅𝐸 = 1 across all scenarios, which is another big difference from 
the simulation in paper.  We assume a situation with only 1 causal locus having true interaction 
with E and others null with no interaction effect. At the causal locus, the prevalence of G is set at 
0.35. G-E odds ratio among controls for the causal locus is set at 3 values, namely, exp(θGE)=1.0, 
0.9, 1.1, corresponding to independence, negative, and positive dependence. The interaction 
parameter at the causal locus RERI=exp(βGE)-1 is varied from 0.1 to 1. Among the M – 1 null loci, 
without any interaction effects with E, the prevalence of G is assumed to be Uniform (0.2, 0.5). 
The population-level G-E association structure among null loci is assumed to be of the form of a 
mixture distribution reflecting that a large fraction, e.g., pind, of the SNPs, indeed, is independent 
of E in the population, whereas the remaining SNPs show some departures from the 
independence assumption. We generated the log odds ratio of the G-E association in controls 
corresponding to null loci as θG0E~pindδ0 + (1 − pind)𝑁(0, 𝑠𝑑 = log (1.5)/2 ). Here, δ0  is a 
point mass at 0 reflecting G-E independence. The standard deviation (sd) parameter of the 
normal distribution part of the mixture is chosen such that, of the θGE values that depart from 
independence, 95% fall within ±log(1.5). We vary the simulation parameter pind from 0.95 to 
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1.0 to create G and E dependence among more null markers. The family-wise type I error rate is 
estimated as the empirical proportion of data sets declaring at least 1 null marker to be significant 
using level of significance α/M. The expected number of false positives is estimated as the 
average number of falsely rejected null hypotheses, averaged over 1000 data sets. We can see 
the type I error of EB test still perform well in genomewide studies. 
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Web Table 10: Power for UML, CML and EB estimator of RERI with 𝐇𝟎: 𝑅𝐸𝑅𝐼 = 0 
Fix: 𝑝𝐺 = 0.2, 𝑝𝐸 = 0.3, 𝑂𝑅𝐺 = 1.2, 𝑂𝑅𝐸 = 1.5, N0 = 𝑁1 = 4000, α = 0.05 
Vary: 𝑅𝐸𝑅𝐼 = (0,1, step = 0.1),  exp(𝜃𝐺𝐸) = (0.8, 1, 1.2)  
 
exp(𝜃𝐺𝐸) RERI UML CML CML* EB EB*  
0 0.049 0.822 0.056 0.085 0.047  
0.1 0.069 0.534 0.008 0.045 0.023  
0.2 0.147 0.253 0.002 0.060 0.030  
0.3 0.317 0.084 0.000 0.155 0.067  
0.4 0.507 0.038 0.000 0.273 0.145 
0.8 0.5 0.672 0.133 0.000 0.442 0.275  
0.6 0.820 0.336 0.000 0.637 0.439  
0.7 0.917 0.594 0.005 0.798 0.617  
0.8 0.957 0.800 0.033 0.903 0.786  
0.9 0.989 0.932 0.116 0.968 0.907  
1 0.997 0.980 0.278 0.992 0.967  
0 0.039 0.053 0.053 0.030 0.030  
0.1 0.069 0.135 0.135 0.091 0.091  
0.2 0.175 0.350 0.350 0.258 0.258  
0.3 0.320 0.659 0.659 0.495 0.495  
0.4 0.509 0.858 0.858 0.712 0.712 
1 0.5 0.693 0.970 0.970 0.870 0.870  
0.6 0.854 0.997 0.997 0.941 0.941  
0.7 0.916 0.999 0.999 0.974 0.974  
0.8 0.978 1.000 1.000 0.994 0.994  
0.9 0.995 1.000 1.000 0.997 0.997  
1 0.997 1.000 1.000 0.999 0.999  
0 0.061 0.645 0.042 0.098 0.049  
0.1 0.083 0.877 0.187 0.177 0.105  
0.2 0.161 0.981 0.482 0.317 0.207  
0.3 0.351 0.999 0.779 0.486 0.356  
0.4 0.540 1.000 0.944 0.665 0.522 
1.2 0.5 0.714 1.000 0.993 0.802 0.718  
0.6 0.858 1.000 0.998 0.920 0.862  
0.7 0.943 1.000 1.000 0.962 0.944  
0.8 0.973 1.000 1.000 0.990 0.973  
0.9 0.995 1.000 1.000 0.999 0.995  
1 0.997 1.000 1.000 0.999 0.998 
* denotes the power at empirical α 
   Empirical α for CML are 10-5 and 10-4 under exp(𝜃𝐺𝐸)=0.8 and 1.2. 
   Empirical α for EB is 0.02 under exp(𝜃𝐺𝐸)=0.8 and 1.2. 
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Web Table 11: Power for UML, CML and EB estimator of RERI with 𝐇𝟎: 𝜓 = 0 
Fix: 𝑝𝐺 = 0.2, 𝑝𝐸 = 0.3, 𝑂𝑅𝐺 = 1.2, 𝑂𝑅𝐸 = 1.5, N0 = 𝑁1 = 4000, α = 0.05 
Vary: 𝑅𝐸𝑅𝐼 = (0,1, step = 0.1),  exp(𝜃𝐺𝐸) = (0.8, 1, 1.2)  
 
exp(𝜃𝐺𝐸) RERI UML CML CML* EB EB*  
0 0.071 0.941 0.172 0.161 0.121  
0.1 0.038 0.818 0.053 0.075 0.053  
0.2 0.061 0.597 0.008 0.065 0.049  
0.3 0.149 0.317 0.002 0.073 0.051  
0.4 0.262 0.160 0.001 0.129 0.089 
0.8 0.5 0.411 0.060 0.000 0.245 0.183  
0.6 0.574 0.062 0.000 0.367 0.291  
0.7 0.703 0.127 0.000 0.488 0.407  
0.8 0.818 0.283 0.002 0.654 0.550  
0.9 0.902 0.498 0.009 0.773 0.707  
1 0.944 0.702 0.027 0.879 0.821  
0 0.074 0.118 0.118 0.084 0.084  
0.1 0.051 0.049 0.049 0.035 0.035  
0.2 0.084 0.117 0.117 0.084 0.084  
0.3 0.128 0.273 0.273 0.188 0.188  
0.4 0.251 0.534 0.534 0.397 0.397 
1 0.5 0.404 0.755 0.755 0.590 0.590  
0.6 0.574 0.911 0.911 0.768 0.768  
0.7 0.703 0.970 0.970 0.857 0.857  
0.8 0.828 0.993 0.993 0.932 0.932  
0.9 0.910 1.000 1.000 0.960 0.960  
1 0.951 1.000 1.000 0.981 0.981  
0 0.087 0.366 0.011 0.068 0.038  
0.1 0.060 0.661 0.055 0.100 0.054  
0.2 0.074 0.878 0.169 0.159 0.100  
0.3 0.154 0.971 0.395 0.282 0.192  
0.4 0.278 0.996 0.681 0.404 0.297 
1.2 0.5 0.435 1.000 0.856 0.557 0.436  
0.6 0.567 1.000 0.957 0.669 0.570  
0.7 0.717 1.000 0.991 0.809 0.726  
0.8 0.825 1.000 0.999 0.891 0.828  
0.9 0.917 1.000 1.000 0.946 0.916  
1 0.948 1.000 1.000 0.967 0.947 
* denotes the power at empirical α 
   Empirical α for CML are 10-5 and 5×10-5 under exp(𝜃𝐺𝐸)=0.8 and 1.2. 
   Empirical α for EB are 0.03 and 0.02 under exp(𝜃𝐺𝐸)=0.8 and 1.2. 
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Web Table 12: Power of Wald test and LRT for 𝑅𝐸𝑅𝐼𝑐𝑚𝑙 
Fix: 𝑝𝐺 = 0.2, 𝑝𝐸 = 0.3, 𝑂𝑅𝐺 = 1.2, 𝑂𝑅𝐸 = 1.5, N0 = 𝑁1 = 4000, α = 0.05 
Vary: 𝑅𝐸𝑅𝐼 = (0,1) with step 0.1,  exp(𝜃𝐺𝐸) = (0.8, 1, 1.2)  
 
exp(𝜃𝐺𝐸) RERI Wald LRT  
0 0.822 0.813  
0.1 0.534 0.520  
0.2 0.253 0.244  
0.3 0.084 0.078  
0.4 0.038 0.043 
0.8 0.5 0.133 0.140  
0.6 0.336 0.353  
0.7 0.594 0.616  
0.8 0.800 0.813  
0.9 0.932 0.934  
1 0.980 0.983  
0 0.053 0.055  
0.1 0.135 0.145  
0.2 0.350 0.371  
0.3 0.659 0.676  
0.4 0.858 0.867 
1 0.5 0.970 0.974  
0.6 0.997 0.999  
0.7 0.999 0.999  
0.8 1.000 1.000  
0.9 1.000 1.000  
1 1.000 1.000  
0 0.645 0.663  
0.1 0.877 0.886  
0.2 0.981 0.982  
0.3 0.999 0.999  
0.4 1.000 1.000 
1.2 0.5 1.000 1.000  
0.6 1.000 1.000  
0.7 1.000 1.000  
0.8 1.000 1.000  
0.9 1.000 1.000  
1 1.000 1.000 
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Web Table 13: Power for UML, CML and EB estimator of RERI with 𝐇𝟎: 𝑅𝐸𝑅𝐼 = 0 
Fix: RERI = 0.5, 𝑂𝑅𝐺 = 1.2, 𝑂𝑅𝐸 = 1.5, N0 = 𝑁1 = 4000, α = 0.05 
Vary: 𝑝𝐺 = (0.1, 0.2, 0.3), 𝑝𝐸 = (0.3, 0.4, 0.5),  exp(𝜃𝐺𝐸) = (0.8, 1, 1.2)  
 
 exp(𝜃𝐺𝐸) 𝑝𝐸 𝑝𝐺 UML CML EB 
 0.3 0.1 0.350 0.072 0.147 
 0.3 0.2 0.672 0.133 0.442 
 0.3 0.3 0.811 0.177 0.628 
 0.4 0.1 0.459 0.088 0.243 
0.8 0.4 0.2 0.776 0.182 0.571 
 0.4 0.3 0.881 0.254 0.761 
 0.5 0.1 0.537 0.139 0.320 
 0.5 0.2 0.821 0.242 0.666 
 0.5 0.3 0.898 0.283 0.792 
 0.3 0.1 0.416 0.837 0.638 
 0.3 0.2 0.693 0.970 0.870 
 0.3 0.3 0.824 0.993 0.925 
 0.4 0.1 0.532 0.877 0.713 
1 0.4 0.2 0.788 0.986 0.915 
 0.4 0.3 0.903 0.995 0.954 
 0.5 0.1 0.563 0.892 0.761 
 0.5 0.2 0.811 0.988 0.915 
 0.5 0.3 0.911 0.998 0.971 
 0.3 0.1 0.444 0.998 0.620 
 0.3 0.2 0.714 1.000 0.802 
 0.3 0.3 0.857 1.000 0.902 
 0.4 0.1 0.550 1.000 0.693 
1.2 0.4 0.2 0.786 1.000 0.875 
 0.4 0.3 0.904 1.000 0.934 
 0.5 0.1 0.583 1.000 0.714 
 0.5 0.2 0.821 1.000 0.876 
 0.5 0.3 0.909 1.000 0.936 
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Web Table 14: Power for UML, CML and EB estimator of RERI with 𝐇𝟎: 𝑅𝐸𝑅𝐼 = 0 
Fix: RERI = 0.5, 𝑝𝐺 = 0.2, 𝑝𝐸 = 0.3, N0 = 𝑁1 = 4000, α = 0.05 
Vary: 𝑂𝑅𝐸 = (1.3, 1.5, 1.7), 𝑂𝑅𝐺 = (1.1, 1.2, 1.3),  exp(𝜃𝐺𝐸) = (0.8, 1, 1.2)  
 
 exp(𝜃𝐺𝐸) 𝑂𝑅𝐸 𝑂𝑅𝐺 UML CML EB 
 1.3 1.1 0.803 0.294 0.597 
 1.3 1.2 0.740 0.193 0.529 
 1.3 1.3 0.707 0.172 0.483 
 1.5 1.1 0.725 0.171 0.505 
0.8 1.5 1.2 0.672 0.133 0.442 
 1.5 1.3 0.636 0.100 0.403 
 1.7 1.1 0.657 0.107 0.397 
 1.7 1.2 0.598 0.080 0.356 
 1.7 1.3 0.577 0.064 0.344 
 1.3 1.1 0.796 0.993 0.931 
 1.3 1.2 0.761 0.988 0.903 
 1.3 1.3 0.748 0.979 0.886 
 1.5 1.1 0.749 0.984 0.893 
1 1.5 1.2 0.693 0.970 0.870 
 1.5 1.3 0.669 0.961 0.848 
 1.7 1.1 0.667 0.958 0.842 
 1.7 1.2 0.634 0.946 0.844 
 1.7 1.3 0.597 0.938 0.806 
 1.3 1.1 0.842 1.000 0.901 
 1.3 1.2 0.795 1.000 0.870 
 1.3 1.3 0.788 1.000 0.856 
 1.5 1.1 0.761 1.000 0.833 
1.2 1.5 1.2 0.714 1.000 0.802 
 1.5 1.3 0.693 1.000 0.791 
 1.7 1.1 0.712 1.000 0.808 
 1.7 1.2 0.683 1.000 0.784 
 1.7 1.3 0.639 1.000 0.745 
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Web Table 15: Power for UML, CML and EB estimator of RERI with 𝐇𝟎: 𝑅𝐸𝑅𝐼 = 0 
Fix: RERI = 0.5, 𝑂𝑅𝐺 = 1.2, 𝑂𝑅𝐸 = 1.5, 𝑝𝐺 = 0.2, 𝑝𝐸 = 0.3 
Vary:  N0 = 𝑁1 = (400, 4000), α = (0.005, 0.05), exp(𝜃𝐺𝐸) = (0.8, 0.9, 1, 1.1, 1.2)  
 
N0 = 𝑁1, α  exp(𝜃𝐺𝐸) UML CML EB  
0.8 0.672 0.133 0.442 
4000 0.9 0.693 0.697 0.676 
0.05 1 0.693 0.970 0.870  
1.1 0.721 1.000 0.846  
1.2 0.714 1.000 0.802 
 0.8 0.300 0.023 0.123 
4000 0.9 0.321 0.328 0.182 
0.005 1 0.346 0.838 0.600  
1.1 0.368 0.995 0.617  
1.2 0.386 1.000 0.512 
 0.8 0.030 0.041 0.012 
400 0.9 0.032 0.090 0.043 
0.05 1 0.044 0.167 0.100  
1.1 0.049 0.287 0.150  
1.2 0.051 0.427 0.213 
 0.8 0.000 0.000 0.000 
400 0.9 0.000 0.005 0.002 
0.005 1 0.000 0.018 0.004  
1.1 0.000 0.028 0.012  
1.2 0.000 0.070 0.020 
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Web Figure 5. Comparison of Power between LRT and Wald Test for CML estimator when 𝑝𝐺 =
0.3, 𝑝𝐸 = 0.3, 𝑂𝑅𝐺 = 1.2, 𝑂𝑅𝐸 = 1.5, 𝑁 = 4000, 𝛼 = 0.05, exp(𝜃𝐺𝐸)=1 and RERI changes from 0 
to 0.5 with a grid level of 0.1. 
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Web Appendix 9. Discussions on absolute relative bias and MSE 
In this section, we first illustrate that 𝑅𝐸𝑅?̂?𝐸𝐵 is preferred to  𝑅𝐸𝑅?̂?𝐸𝐵1 and 𝑅𝐸𝑅?̂?𝐸𝐵2  as described 
in Remark 1, in terms of MSE, then we compare the absolute relative bias (ARB) and MSE of 
𝑅𝐸𝑅?̂?𝑢𝑚𝑙 , 𝑅𝐸𝑅?̂?𝑐𝑚𝑙 and 𝑅𝐸𝑅?̂?𝐸𝐵 (Web Tables 16-19). Compared to 𝑅𝐸𝑅?̂?𝐸𝐵, 𝑅𝐸𝑅?̂?𝐸𝐵1 puts more 
weight on the CML estimator and it has a larger MSE in 26 of 48 parameter settings. In contrast, 
𝑅𝐸𝑅?̂?𝐸𝐵2 puts more weight on UML estimator and it has a larger MSE in 32 of 48 parameter 
settings. Thus, we choose 𝑅𝐸𝑅?̂?𝐸𝐵 as the proposed empirical Bayes estimator. Next, we compare 
the ARB of  𝑅𝐸𝑅?̂?𝑢𝑚𝑙 , 𝑅𝐸𝑅?̂?𝑐𝑚𝑙 and 𝑅𝐸𝑅?̂?𝐸𝐵 under different strengths of G-E association. Without 
loss of generality, let us see the ARB at RERI=0.5 for example. UML is always an unbiased 
estimator, and the ARB of EB (0.157) is 20% less than that of CML (0.773) when exp(θGE)=0.8. 
Finally, we compare the MSE of the three estimators at RERI=0.5. When exp(θGE)=0.8, the MSE 
of EB (0.103) is 56% of CML (0.182) but 12% higher than UML (0.092). When exp(θGE)=1, the 
MSE of EB (0.054) is 65% of UML (0.083) but 50% higher than CML (0.036). In summary, EB is 
always intermediate between UML and CML, and it leans towards either UML or CML which has 
a smaller ARB and MSE depending on exp(θGE) (Web Figure 6). 
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Web Table 16: Absolute relative bias, variance and MSE of 𝑅𝐸𝑅?̂?𝐸𝐵, 𝑅𝐸𝑅?̂?𝐸𝐵1 and 𝑅𝐸𝑅?̂?𝐸𝐵2 
Fix: 𝑂𝑅𝐺 = 1.2, 𝑂𝑅𝐸 = 1.5, 𝑝𝐺 = 0.2, 𝑝𝐸 = 0.3, N0 = 𝑁1 = 4000  
Vary:  exp(𝜃𝐺𝐸) = (0.8, 1, 1.2), 𝑅𝐸𝑅𝐼 = (0,1.5) with a grid level of 0.1 
 
 exp(𝜃𝐺𝐸) RERI 
Absolute Relative Bias Variance MSE 
EB EB1 EB2 EB EB1 EB2 EB EB1 EB1 
 0 Inf Inf Inf 0.037 0.032 0.040 0.078 0.079 0.083 
 0.1 0.671 1.244 0.500 0.040 0.035 0.044 0.085 0.085 0.090 
 0.2 0.347 0.668 0.243 0.043 0.036 0.047 0.090 0.090 0.096 
 0.3 0.225 0.462 0.143 0.043 0.036 0.048 0.091 0.091 0.098 
 0.4 0.181 0.378 0.110 0.045 0.037 0.051 0.096 0.096 0.104 
 0.5 0.154 0.325 0.089 0.051 0.041 0.058 0.108 0.108 0.118 
 0.6 0.140 0.295 0.079 0.053 0.042 0.061 0.113 0.114 0.123 
0.8 0.7 0.119 0.263 0.061 0.055 0.042 0.063 0.117 0.117 0.128 
 0.8 0.098 0.236 0.042 0.058 0.043 0.067 0.123 0.122 0.135 
 0.9 0.098 0.229 0.044 0.064 0.047 0.074 0.136 0.135 0.150 
 1 0.084 0.211 0.031 0.068 0.049 0.079 0.143 0.142 0.158 
 1.1 0.082 0.205 0.031 0.068 0.048 0.079 0.143 0.146 0.159 
 1.2 0.076 0.195 0.025 0.075 0.051 0.087 0.157 0.158 0.175 
 1.3 0.074 0.192 0.024 0.076 0.050 0.090 0.162 0.162 0.182 
 1.4 0.071 0.186 0.021 0.082 0.054 0.097 0.174 0.175 0.195 
 1.5 0.067 0.180 0.017 0.082 0.052 0.097 0.173 0.178 0.194 
 0 Inf Inf Inf 0.023 0.019 0.024 0.045 0.038 0.047 
 0.1 0.026 0.026 0.014 0.023 0.019 0.024 0.046 0.038 0.048 
 0.2 0.001 0.002 0.006 0.023 0.019 0.025 0.047 0.039 0.050 
 0.3 0.004 0.004 0.001 0.025 0.020 0.027 0.051 0.041 0.054 
 0.4 0.000 0.001 0.004 0.028 0.023 0.030 0.056 0.045 0.061 
 0.5 0.007 0.007 0.004 0.031 0.025 0.034 0.062 0.050 0.069 
1 0.6 0.001 0.000 0.003 0.032 0.026 0.035 0.064 0.051 0.070 
 0.7 0.000 0.001 0.002 0.033 0.026 0.036 0.065 0.051 0.073 
 0.8 0.005 0.005 0.002 0.036 0.028 0.040 0.072 0.055 0.081 
 0.9 0.004 0.004 0.002 0.035 0.027 0.039 0.069 0.055 0.078 
 1 0.001 0.001 0.001 0.036 0.028 0.041 0.072 0.056 0.082 
 1.1 0.000 0.000 0.002 0.042 0.033 0.048 0.084 0.065 0.096 
 1.2 0.002 0.002 0.004 0.040 0.031 0.046 0.080 0.063 0.093 
 1.3 0.002 0.002 0.003 0.041 0.032 0.047 0.082 0.064 0.095 
 1.4 0.005 0.005 0.007 0.047 0.036 0.055 0.094 0.072 0.110 
 1.5 0.005 0.004 0.006 0.051 0.039 0.059 0.101 0.077 0.118 
 0 Inf Inf Inf 0.034 0.031 0.033 0.073 0.076 0.071 
 0.1 0.736 1.234 0.617 0.035 0.032 0.035 0.075 0.080 0.073 
 0.2 0.380 0.655 0.307 0.039 0.035 0.039 0.084 0.088 0.082 
 0.3 0.264 0.466 0.206 0.039 0.036 0.040 0.085 0.091 0.083 
 0.4 0.206 0.372 0.155 0.044 0.039 0.044 0.094 0.100 0.093 
29 
 
 0.5 0.168 0.312 0.121 0.047 0.041 0.048 0.100 0.107 0.099 
1.2 0.6 0.139 0.268 0.095 0.050 0.044 0.051 0.106 0.113 0.106 
 0.7 0.128 0.247 0.085 0.053 0.046 0.055 0.113 0.122 0.113 
 0.8 0.124 0.237 0.082 0.046 0.042 0.047 0.102 0.121 0.099 
 0.9 0.106 0.213 0.065 0.053 0.048 0.055 0.115 0.133 0.112 
 1 0.106 0.209 0.065 0.055 0.050 0.058 0.122 0.143 0.120 
 1.1 0.098 0.197 0.058 0.057 0.051 0.059 0.125 0.150 0.122 
 1.2 0.088 0.184 0.049 0.060 0.055 0.063 0.132 0.158 0.129 
 1.3 0.083 0.177 0.044 0.065 0.059 0.067 0.140 0.170 0.137 
 1.4 0.080 0.171 0.041 0.066 0.060 0.069 0.145 0.178 0.142 
 1.5 0.080 0.170 0.042 0.077 0.068 0.082 0.168 0.201 0.167 
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Web Table 17: Absolute relative bias, variance and MSE of 𝑅𝐸𝑅?̂?𝑢𝑚𝑙, 𝑅𝐸𝑅?̂?𝑐𝑚𝑙 and 𝑅𝐸𝑅?̂?𝐸𝐵 
Fix: 𝑂𝑅𝐺 = 1.2,  𝑂𝑅𝐸 = 1.5, 𝑝𝐺 = 0.2, 𝑝𝐸 = 0.3, N0 = 𝑁1 = 4000  
Vary:  exp(𝜃𝐺𝐸) = (0.8, 0.9, 1, 1.1, 1.2), 𝑅𝐸𝑅𝐼 = (0,1.5) with a grid level of 0.1 
 exp(𝜃𝐺𝐸) RERI 
Absolute Relative Bias Variance MSE 
UML CML EB UML CML EB UML CML EB 
 0 Inf Inf Inf 0.033 0.013 0.033 0.067 0.135 0.075 
 0.1 0.082 3.410 0.680 0.034 0.014 0.034 0.070 0.144 0.079 
 0.2 0.030 1.770 0.362 0.037 0.014 0.037 0.075 0.153 0.084 
 0.3 0.034 1.206 0.236 0.039 0.014 0.039 0.080 0.160 0.089 
 0.4 0.012 0.943 0.196 0.039 0.015 0.039 0.083 0.173 0.094 
 0.5 0.015 0.773 0.157 0.046 0.016 0.046 0.092 0.182 0.103 
 0.6 0.011 0.664 0.136 0.046 0.017 0.046 0.095 0.192 0.107 
0.8 0.7 0.011 0.585 0.120 0.053 0.018 0.053 0.105 0.203 0.117 
 0.8 0.010 0.526 0.107 0.055 0.018 0.055 0.110 0.214 0.123 
 0.9 0.009 0.480 0.098 0.056 0.020 0.056 0.114 0.225 0.127 
 1 0.012 0.439 0.087 0.060 0.022 0.060 0.121 0.235 0.135 
 1.1 0.010 0.410 0.083 0.056 0.021 0.056 0.121 0.246 0.135 
 1.2 0.008 0.387 0.080 0.068 0.022 0.067 0.136 0.260 0.151 
 1.3 0.006 0.367 0.077 0.072 0.026 0.072 0.144 0.277 0.161 
 1.4 0.008 0.347 0.071 0.074 0.025 0.074 0.150 0.285 0.167 
 1.5 0.011 0.328 0.065 0.081 0.027 0.080 0.161 0.295 0.177 
 0 Inf Inf Inf 0.032 0.013 0.025 0.065 0.051 0.057 
 0.1 0.025 1.669 0.649 0.034 0.014 0.026 0.069 0.056 0.061 
 0.2 0.009 0.841 0.314 0.034 0.014 0.027 0.071 0.057 0.063 
 0.3 0.001 0.584 0.222 0.037 0.015 0.028 0.075 0.061 0.067 
 0.4 0.001 0.450 0.170 0.039 0.016 0.030 0.080 0.064 0.070 
 0.5 0.003 0.370 0.138 0.042 0.016 0.032 0.085 0.068 0.075 
0.9 0.6 0.006 0.314 0.116 0.045 0.018 0.034 0.091 0.072 0.080 
 0.7 0.006 0.275 0.101 0.048 0.019 0.036 0.096 0.075 0.084 
 0.8 0.002 0.251 0.094 0.048 0.020 0.037 0.100 0.080 0.088 
 0.9 0.002 0.229 0.086 0.051 0.021 0.039 0.106 0.084 0.092 
 1 0.005 0.208 0.076 0.056 0.023 0.043 0.114 0.089 0.099 
 1.1 0.002 0.196 0.074 0.057 0.025 0.044 0.118 0.095 0.104 
 1.2 0.002 0.185 0.070 0.061 0.024 0.046 0.125 0.098 0.110 
 1.3 0.003 0.174 0.065 0.063 0.026 0.048 0.131 0.103 0.115 
 1.4 0.005 0.163 0.060 0.070 0.028 0.054 0.141 0.107 0.123 
 1.5 0.004 0.157 0.058 0.076 0.030 0.057 0.150 0.114 0.130 
 0 Inf Inf Inf 0.030 0.014 0.019 0.061 0.028 0.040 
 0.1 0.020 0.018 0.029 0.033 0.015 0.021 0.066 0.029 0.044 
 0.2 0.007 0.008 0.013 0.036 0.015 0.023 0.071 0.031 0.047 
 0.3 0.006 0.006 0.010 0.036 0.016 0.023 0.073 0.032 0.048 
 0.4 0.011 0.011 0.014 0.040 0.018 0.026 0.079 0.035 0.053 
 0.5 0.002 0.003 0.005 0.041 0.018 0.026 0.083 0.036 0.054 
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1 0.6 0.002 0.003 0.005 0.043 0.019 0.028 0.087 0.038 0.058 
 0.7 0.002 0.003 0.005 0.049 0.022 0.031 0.095 0.042 0.063 
 0.8 0.001 0.000 0.001 0.048 0.022 0.031 0.098 0.043 0.064 
 0.9 0.005 0.004 0.002 0.053 0.023 0.033 0.105 0.046 0.069 
 1 0.001 0.001 0.001 0.055 0.027 0.036 0.110 0.051 0.074 
 1.1 0.001 0.003 0.004 0.060 0.026 0.039 0.118 0.052 0.079 
 1.2 0.001 0.003 0.004 0.063 0.027 0.040 0.124 0.054 0.082 
 1.3 0.010 0.009 0.007 0.064 0.030 0.041 0.129 0.059 0.086 
 1.4 0.005 0.003 0.002 0.070 0.030 0.044 0.138 0.061 0.091 
 1.5 0.005 0.004 0.003 0.069 0.032 0.045 0.141 0.064 0.093 
 0 Inf Inf Inf 0.032 0.014 0.026 0.062 0.050 0.054 
 0.1 0.010 1.476 0.557 0.034 0.016 0.028 0.066 0.053 0.058 
 0.2 0.016 0.751 0.275 0.033 0.016 0.027 0.067 0.054 0.058 
 0.3 0.014 0.541 0.213 0.035 0.017 0.028 0.071 0.061 0.062 
 0.4 0.001 0.407 0.154 0.036 0.018 0.029 0.074 0.062 0.064 
 0.5 0.005 0.340 0.131 0.039 0.018 0.031 0.079 0.067 0.069 
1.1 0.6 0.001 0.285 0.107 0.043 0.021 0.034 0.085 0.070 0.073 
 0.7 0.005 0.257 0.099 0.044 0.021 0.035 0.089 0.075 0.077 
 0.8 0.000 0.227 0.086 0.046 0.023 0.038 0.094 0.079 0.082 
 0.9 0.003 0.209 0.081 0.048 0.024 0.039 0.099 0.084 0.086 
 1 0.005 0.195 0.076 0.054 0.026 0.044 0.107 0.090 0.094 
 1.1 0.005 0.183 0.072 0.055 0.028 0.045 0.111 0.096 0.097 
 1.2 0.004 0.170 0.067 0.056 0.028 0.045 0.115 0.099 0.100 
 1.3 0.009 0.167 0.069 0.061 0.031 0.050 0.123 0.109 0.109 
 1.4 0.010 0.159 0.066 0.063 0.034 0.052 0.128 0.117 0.114 
 1.5 0.008 0.150 0.062 0.069 0.035 0.057 0.138 0.121 0.122 
 0 Inf Inf Inf 0.031 0.015 0.031 0.061 0.108 0.068 
 0.1 0.021 2.850 0.688 0.033 0.016 0.033 0.064 0.113 0.071 
 0.2 0.005 1.478 0.359 0.033 0.016 0.033 0.066 0.120 0.073 
 0.3 0.000 1.019 0.250 0.035 0.018 0.035 0.070 0.129 0.078 
 0.4 0.004 0.783 0.188 0.039 0.019 0.039 0.076 0.136 0.084 
 0.5 0.002 0.645 0.156 0.042 0.020 0.042 0.081 0.145 0.090 
1.2 0.6 0.003 0.552 0.132 0.043 0.023 0.045 0.084 0.154 0.094 
 0.7 0.003 0.491 0.122 0.047 0.025 0.047 0.090 0.166 0.101 
 0.8 0.004 0.443 0.111 0.049 0.026 0.049 0.095 0.176 0.106 
 0.9 0.005 0.405 0.102 0.049 0.026 0.049 0.098 0.185 0.109 
 1 0.001 0.371 0.092 0.051 0.027 0.051 0.102 0.193 0.114 
 1.1 0.006 0.351 0.090 0.056 0.030 0.056 0.110 0.209 0.124 
 1.2 0.009 0.332 0.088 0.056 0.031 0.056 0.112 0.222 0.128 
 1.3 0.009 0.315 0.084 0.062 0.035 0.062 0.122 0.236 0.137 
 1.4 0.006 0.297 0.078 0.065 0.037 0.065 0.128 0.245 0.144 
 1.5 0.010 0.287 0.078 0.066 0.038 0.066 0.132 0.261 0.151 
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Web Table 18: Absolute relative bias, variance and MSE of 𝑅𝐸𝑅?̂?𝑢𝑚𝑙, 𝑅𝐸𝑅?̂?𝑐𝑚𝑙 and 𝑅𝐸𝑅?̂?𝐸𝐵 
Fix: 𝑅𝐸𝑅𝐼 = 0.5, 𝑝𝐺 = 0.2, 𝑝𝐸 = 0.3, N0 = 𝑁1 = 4000  
Vary: 𝑂𝑅𝐸 = (1.3, 1.5, 1.7), 𝑂𝑅𝐺 = (1.1, 1.2, 1.3), exp(𝜃𝐺𝐸) = (0.9, 1, 1.1) 
 
 exp(𝜃𝐺𝐸) 𝑂𝑅𝐸 𝑂𝑅𝐺 
ARB Variance MSE 
UML CML EB UML CML EB UML CML EB 
 1.3 1.1 0.004 0.330 0.129 0.032 0.013 0.024 0.065 0.054 0.058 
 1.3 1.2 0.001 0.344 0.131 0.035 0.015 0.026 0.071 0.059 0.063 
 1.3 1.3 0.003 0.362 0.138 0.040 0.015 0.031 0.080 0.064 0.071 
 1.5 1.1 0.005 0.351 0.131 0.039 0.015 0.030 0.079 0.062 0.070 
0.9 1.5 1.2 0.003 0.370 0.138 0.042 0.016 0.032 0.085 0.068 0.075 
 1.5 1.3 0.008 0.381 0.138 0.048 0.017 0.037 0.095 0.072 0.083 
 1.7 1.1 0.007 0.378 0.140 0.045 0.018 0.035 0.092 0.072 0.081 
 1.7 1.2 0.002 0.399 0.150 0.049 0.020 0.037 0.099 0.080 0.087 
 1.7 1.3 0.000 0.419 0.158 0.052 0.021 0.040 0.107 0.086 0.094 
 1.3 1.1 0.005 0.005 0.007 0.032 0.015 0.020 0.065 0.029 0.043 
 1.3 1.2 0.004 0.005 0.007 0.037 0.015 0.023 0.073 0.031 0.047 
 1.3 1.3 0.003 0.003 0.006 0.037 0.017 0.023 0.075 0.034 0.050 
 1.5 1.1 0.004 0.003 0.000 0.038 0.017 0.024 0.077 0.034 0.051 
1 1.5 1.2 0.002 0.003 0.005 0.041 0.018 0.026 0.083 0.036 0.054 
 1.5 1.3 0.001 0.001 0.004 0.044 0.021 0.028 0.090 0.040 0.059 
 1.7 1.1 0.005 0.005 0.002 0.044 0.020 0.027 0.089 0.040 0.058 
 1.7 1.2 0.002 0.002 0.002 0.046 0.021 0.029 0.094 0.042 0.062 
 1.7 1.3 0.000 0.000 0.003 0.052 0.023 0.033 0.104 0.045 0.069 
 1.3 1.1 0.009 0.302 0.120 0.031 0.015 0.025 0.062 0.053 0.055 
 1.3 1.2 0.009 0.317 0.126 0.033 0.016 0.027 0.068 0.058 0.059 
 1.3 1.3 0.009 0.333 0.130 0.037 0.018 0.030 0.074 0.064 0.065 
 1.5 1.1 0.004 0.323 0.125 0.036 0.018 0.029 0.074 0.062 0.064 
1.1 1.5 1.2 0.005 0.340 0.131 0.039 0.018 0.031 0.079 0.067 0.069 
 1.5 1.3 0.008 0.358 0.139 0.043 0.021 0.034 0.087 0.073 0.076 
 1.7 1.1 0.003 0.349 0.134 0.043 0.020 0.034 0.086 0.072 0.075 
 1.7 1.2 0.010 0.372 0.146 0.045 0.022 0.036 0.092 0.079 0.081 
 1.7 1.3 0.007 0.383 0.147 0.051 0.023 0.040 0.101 0.084 0.088 
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Web Table 19: Absolute relative bias, variance and MSE of 𝑅𝐸𝑅?̂?𝑢𝑚𝑙, 𝑅𝐸𝑅?̂?𝑐𝑚𝑙 and 𝑅𝐸𝑅?̂?𝐸𝐵 
Fix: 𝑅𝐸𝑅𝐼 = 0.5, 𝑂𝑅𝐸 = 1.5, 𝑂𝑅𝐺 = 1.2, N0 = 𝑁1 = 4000  
Vary: 𝑝𝐺 = (0.1, 0.2, 0.3), 𝑝𝐸 = (0.3, 0.4, 0.5) , exp(𝜃𝐺𝐸) = (0.9, 1, 1.1) 
 
 exp(𝜃𝐺𝐸) 𝑝𝐸 𝑝𝐺 
ARB Variance MSE 
UML CML EB UML CML EB UML CML EB 
 0.3 0.1 0.000 0.381 0.163 0.083 0.029 0.056 0.166 0.095 0.130 
 0.3 0.2 0.003 0.370 0.138 0.042 0.016 0.032 0.085 0.068 0.075 
 0.3 0.3 0.008 0.357 0.133 0.030 0.013 0.025 0.061 0.058 0.057 
 0.4 0.1 0.018 0.363 0.135 0.068 0.025 0.049 0.135 0.084 0.109 
0.9 0.4 0.2 0.018 0.334 0.113 0.038 0.016 0.031 0.073 0.059 0.066 
 0.4 0.3 0.020 0.324 0.097 0.027 0.012 0.023 0.053 0.050 0.049 
 0.5 0.1 0.013 0.333 0.130 0.059 0.027 0.043 0.118 0.080 0.096 
 0.5 0.2 0.003 0.333 0.121 0.032 0.014 0.025 0.063 0.057 0.057 
 0.5 0.3 0.011 0.315 0.102 0.023 0.012 0.020 0.045 0.048 0.043 
 0.3 0.1 0.017 0.010 0.008 0.082 0.031 0.049 0.161 0.064 0.104 
 0.3 0.2 0.002 0.003 0.005 0.041 0.018 0.026 0.083 0.036 0.054 
 0.3 0.3 0.008 0.002 0.009 0.033 0.014 0.021 0.063 0.027 0.042 
 0.4 0.1 0.019 0.000 0.007 0.065 0.026 0.040 0.130 0.054 0.085 
1 0.4 0.2 0.013 0.011 0.007 0.036 0.016 0.022 0.070 0.032 0.046 
 0.4 0.3 0.006 0.006 0.002 0.025 0.012 0.016 0.049 0.024 0.034 
 0.5 0.1 0.006 0.001 0.005 0.057 0.027 0.037 0.115 0.054 0.078 
 0.5 0.2 0.009 0.004 0.005 0.033 0.015 0.021 0.063 0.030 0.043 
 0.5 0.3 0.007 0.002 0.006 0.023 0.011 0.015 0.045 0.023 0.031 
 0.3 0.1 0.002 0.356 0.136 0.074 0.035 0.056 0.150 0.101 0.118 
 0.3 0.2 0.005 0.340 0.131 0.039 0.018 0.031 0.079 0.067 0.069 
 0.3 0.3 0.004 0.320 0.118 0.032 0.014 0.026 0.061 0.054 0.055 
 0.4 0.1 0.007 0.332 0.136 0.057 0.028 0.043 0.119 0.086 0.096 
1.1 0.4 0.2 0.016 0.326 0.134 0.034 0.018 0.028 0.067 0.061 0.060 
 0.4 0.3 0.014 0.311 0.121 0.026 0.013 0.022 0.050 0.049 0.047 
 0.5 0.1 0.023 0.322 0.146 0.056 0.029 0.042 0.113 0.083 0.093 
 0.5 0.2 0.014 0.290 0.101 0.031 0.015 0.025 0.062 0.052 0.054 
 0.5 0.3 0.009 0.287 0.099 0.023 0.012 0.020 0.045 0.044 0.042 
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Web Figure 6. Absolute relative bias and MSE for UML, CML, EB estimator of RERI under nine 
settings:  data generated on 4000 cases and 4000 controls with 1000 replications under RERI=0.5, 
1, 1.5, corresponding multiplicative interaction 1.22, 1.5, 1.78 and fixed parameters 𝑝𝐺 = 0.2, 
𝑝𝐸 = 0.3 , 𝑂𝑅𝐺 = 1.2 , 𝑂𝑅𝐸 = 1.5 . The top panel corresponds to the absolute relative bias, 
whereas the bottom panel corresponds to the MSE. The left, center, and right panels correspond 
to different values of the G-E odds ratio, i.e. exp(𝜃𝐺𝐸)=0.8, 1, 1.2. 
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